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The number of neutrophils in the blood is tightly regulated to ensure adequate
protection against microbial pathogens while minimizing damage to host tissue.
Neutrophil homeostasis in the blood is achieved through a balance of neutrophil
production, release from the bone marrow, and clearance from the circulation.
Accumulating evidence suggests that chemokine signaling in the bone marrow may play
a key role in maintaining neutrophil homeostasis. Based on this evidence, we developed
a “tug-of-war” model in which opposing chemokine gradients, specifically releaseinducing CXCR2 signals and retention-promoting CXCR4 signals, act antagonistically to
regulate neutrophil release from the bone marrow. We generated mice with neutrophils
genetically deficient for the receptors CXCR2 (CXCR2-/-), CXCR4 (CXCR4-/-), or both
(double knock-out or DKO) in order to define the mechanisms by which chemokine
signals regulate neutrophil homeostasis.

ii

We show that CXCR4 negatively regulates neutrophil release from the bone
marrow in a cell autonomous fashion. However, CXCR4 is dispensable for neutrophil
clearance from the circulation. Neutrophil mobilization responses to granulocyte colony
stimulating factor (G-CSF), CXCL2, or Listeria monocytogenes infection are absent or
impaired in CXCR4-/- neutrophils, suggesting that disruption of CXCR4 signaling may be
a common step mediating neutrophil release.
CXCR2-/- neutrophils exhibit abnormal retention in the bone marrow and a
peripheral neutropenia, which replicates the phenotype of the human disease
myelokathexis and indicates that CXCR2 positively regulates neutrophil release from the
bone marrow. CXCR2-/- neutrophils do not mobilize in response to an inhibitor of
CXCR4 and have an impaired response to G-CSF, suggesting that neutrophil release
requires the coordinated regulation of CXCR2 and CXCR4 signals. However, DKO
neutrophils exhibit a shift from the bone marrow to the blood that is similar to CXCR4-/cells, indicating that CXCR4 is dominant to CXCR2 and that there are likely to be
CXCR2-independent mechanisms for directing neutrophil release.
Finally, we show that there is differential production of CXCR2 and CXCR4
ligands by bone marrow osteoblasts and endothelial cells that can be regulated by G-CSF.
Taken together, our data suggest that coordinated osteoblast and endothelial production
of CXCR2 and CXCR4 ligands is a common mechanism controlling neutrophil release
from the bone marrow.
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Chapter 1

Introduction
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1.1

Overview and goals

The overall goal of this project was to characterize mechanisms that regulate circulating
neutrophil counts and thus the ability of neutrophils to traffic to sites of inflammation and
perform their various anti-bacterial functions. Particular emphasis was placed on factors
governing neutrophil mobilization (the release of neutrophils from the bone marrow, the
site of neutrophil production and maturation, into the blood) under either basal or
inflammatory conditions.
The number of circulating neutrophils is tightly regulated in order to effectively
protect against microbial pathogens while minimizing damage to host tissue. Homeostatic
control of neutrophils in the blood is achieved through a balance of neutrophil
production, release from the bone marrow, and clearance from the circulation.
Accumulating evidence suggests that signaling by the chemokine CXCL12 (SDF-1),
through its major receptor CXCR4, plays a key role in controlling neutrophil homeostasis
by acting as a bone marrow retention signal. Alteration of CXCR4 signaling by genetic
mutations, pharmacologic agents, or an inflammatory stimulus changes the number of
circulating neutrophils. The role of CXCR4 in regulating neutrophil homeostasis under
basal and stress conditions is investigated using a genetically defined model in Chapter 2
of this thesis. However, recent genetic data in humans and work detailed in Chapter 3 of
this thesis have implicated additional chemokines and chemokine receptors in the
regulation of neutrophil homeostasis. In Chapter 3, the role of CXCR2 chemokines in
neutrophil trafficking from the bone marrow is investigated using neutrophils genetically
deficient for CXCR2.
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The work in this thesis supports the hypothesis that the degree of neutrophil
mobilization is regulated by the balance of retention-promoting CXCL12/CXCR4 signals
and release-inducing CXCR2 signals. We show that this may be a shared mechanism of
action among diverse types of mobilizing agents. Our experiments delineate the cellintrinsic and cell-extrinsic effects of CXCR2 and CXCR4 in the regulation of neutrophil
trafficking. We investigate the role of these chemokines in neutrophil migration from the
circulation into peripheral tissues and subsequent clearance. Finally, we begin to
characterize the cellular sources of chemokines within the bone marrow. This thesis
provides a more detailed picture of chemokine functions in neutrophil biology.
Dysregulated neutrophil counts are implicated in numerous disease states, from bacterial
infections in the setting of inherited or iatrogenic neutropenia to inflammatory diseases
like atherosclerosis or arthritis that are associated with excessive neutrophils. Therefore,
this work also increases our understanding of the pathophysiology and suggests potential
treatments of some of these diseases.

1.2

Homeostatic control of circulating neutrophil counts

Neutrophils are leukocytes comprising a key component of the innate immune system,
and they play a primary role in establishing an inflammatory response. Their main
functions are to phagocytose and kill bacteria while also producing inflammatory
mediators that allow resolution of the infection and establishment of long-lasting,
adaptive immunity via other cells of the immune system. Patients with congenital or
acquired neutropenia are extremely susceptible to severe, life-threatening bacterial
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infections, although the advent of antibiotic and cytokine therapy has lessened this risk
(1, 2). Conversely, excessive neutrophil accumulation at sites of inflammation can
damage host tissue and contributes to disease pathogenesis in a number of acute and
chronic human diseases. For example, neutrophils are thought to be key mediators of
disease in acute respiratory distress syndrome and rheumatoid arthritis. In murine models
of atherosclerosis (3) and autoimmune encephalitis(4), neutrophils have been shown to
play a causative role in the disease process. Thus, circulating neutrophil counts must be
tightly controlled in order to minimize the risk from both infectious and inflammatory
disease.

1.2.1

Normal baseline neutrophil counts and clinical relevance

Neutrophil counts exhibit little variation within an individual during times of health, but
there is considerable variation between individuals (Figure 1-1A) (5). This variation is
likely to have a genetic basis, as it is dependent on ethnic background. In a large
population study, Caucasians had a mean neutrophil count of 4.4 x 109/L, while that of
African Americans was 3.65 x 109/L. Mice also exhibit variation that is dependent on
genetic background (Figure 1-1B). Of note, whole genome association studies in model
organisms have revealed chromosomal regions associated with neutrophil counts,
including a region containing the CXCR2 chemokine CXCL8, but specific
polymorphisms and their functional consequences were not identified (6).
In humans, total white blood cell counts (WBC) at baseline are mostly determined
by their main component, neutrophils. Underscoring the importance of the regulation of
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neutrophil counts, variation in WBCs has been associated with increased mortality. In
one study, as WBC and neutrophil, but not lymphocyte, counts moved away from a
central number (approximately the mean of the population), they were associated with
increased all-cause mortality (Figure 1-1C). Excessively low counts would predispose to
infection with common pathogens, while increased counts are independent risk factors for
cardiovascular (7) and cancer mortality (8). Notably, mice have much lower circulating
neutrophil counts than humans and also do not naturally develop cardiovascular disease
(Figure 1-1B,C). These observations are concordant with accumulating research
demonstrating that inflammation plays a key role in both cardiovascular disease and
cancer. It is unclear whether alterations in neutrophil homeostasis play a causative role in
these diseases or simply reflect underlying inflammatory processes.

1.2.2

Kinetics of neutrophil production and clearance

Given their key role in both infectious and inflammatory diseases, precise regulation of
circulating neutrophil levels is therefore required. In the average man, over 100 billion
mature neutrophils must enter the circulation from the bone marrow each day in order to
maintain homeostasis; the blood neutrophil pool is turned over 2.3 times each day with a
half-time of disappearance from the blood of only 6.8 hours (2, 9, 10). The bone marrow
postmitotic transit time is 4 days in mice (11) and 7 days in humans (12), demonstrating
that the vast majority of post-mitotic neutrophil lineage cells are stored in the bone
marrow. In comparison to a turnover rate on the order of months for erythrocytes, the
rapid kinetics of neutrophils show that complex yet precise regulatory mechanisms are

5

likely to control neutrophils. At another level of regulatory complexity, circulating
neutrophil numbers are rapidly increased in response to infectious stimuli or other stress
conditions in a process termed “emergency granulopoiesis”.
Neutrophil homeostasis (5, 13) is determined by regulation of three main
processes: neutrophil production in the bone marrow, neutrophil release from the bone
marrow into the circulation, and neutrophil clearance from the blood by adhesion,
transmigration, apoptosis, and phagocytosis in the tissues. As detailed below, much
research has been directed toward describing neutrophil responses in health and disease
and determining the processes, cell types, molecules, and signaling pathways that
regulate these responses. However, many questions remain incompletely answered.

1.3

Neutrophil production

The production and maturation of neutrophils in the bone marrow, or granulopoiesis, is
the process by which a small number of pluripotent, self-renewing hematopoietic stem
cells give rise to mature neutrophils through a number of cell division and differentiation
steps. Stem cells give rise to increasingly differentiated progenitor cells (14).
Granulocyte progenitors undergo characteristic differentiation through myeloblast,
promyelocyte, myelocyte, and metamyelocyte forms before becoming mature
polymorphonuclear granulocytes (PMNs) that can be described as either band or the more
mature segmented form depending on the morphology of the nucleus. It is now known
that the development of different lineages of hematopoietic cells (lymphocyte, erythroid,
megakaryocyte, myeloid and subsets thereof) is governed by specific cytokines providing
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extracellular signals to less differentiated cells and the subsequent activation or
repression of transcriptional programs by characteristic transcription factors. To
characterize these transcriptional programs, Theilgard-Monch et al undertook a
comprehensive microarray analysis of gene expression in cells at various stages of
neutrophilic differentiation (15). They showed that neutrophil maturation was associated
with a downregulation of proliferative networks, engagement of various anti-apoptotic
pathways, expression of host defense effector molecules, and, only upon terminal
differentiation, the acquisition of receptors required to activate neutrophil host defense
functions.

1.3.1

Transcriptional control

Several recent reviews have covered the transcription factors that regulate neutrophil
development and differentiation (16-18). Briefly, the main transcription factors
governing myeloid development, in order from earliest to latest, are PU.1, CCAAT
enhancer binding proteins alpha and epsilon (C/EBPα and C/EBPε), and GFI-1. Genetic
deletion of any of these factors results in blocks at specific stages of differentiation and
absence of the appropriate progeny cells. PU.1 is required for the formation of common
myeloid progenitors (CMP) and the production of B lymphocytes, monocytes,
neutrophils, and eosinophils. C/EBPα is a later transcription factor that is necessary to
form granulocyte/monocyte progenitors (GMP) and produce mature cells of those
lineages. C/EBPε and GFI-1 are necessary and non-redundant for the final stages of
neutrophil maturation, as mice lacking either of these proteins have a differentiation

7

block at the promyelocyte stage and absent or abnormal neutrophil production. The
block is associated with a lack of the secondary and tertiary granule proteins that are
characteristic of mature granulocytes. Subsequent studies utilizing conditional
expression or more precise assays have shown all of these transcription factors to have
additional, overlapping functions in many other hematopoietic processes, particularly in
regulating hematopoietic stem cell function and providing a “differentiation block”
though to be necessary in the pathogenesis of leukemia. Specifically, PU.1 (19) and
C/EBPα (20) mutations or suppression of these genes by the leukemogenic fusion protein
PML-RARα (21) are associated with acute myeloid leukemia (AML). A small subset of
severe congenital neutropenia cases has been associated with mutations in the
transcription factors GFI-1, HAX-1, and LEF-1 (22, 23).

1.3.2

G-CSF: The principle cytokine controlling granulopoiesis

In addition to intrinsic transcription factors governing the production of neutrophils in the
bone marrow, extrinsic signals are also required. For hematopoietic cells in general, one
of the key mechanisms of extrinsic regulation is by cytokines and growth factors, and the
essential cytokine controlling neutrophil production is the granulocyte colony stimulating
factor, or G-CSF (reviewed in Basu et al (24) and Panopoulos and Watowich (25)). GCSF was one of the first cytokines to be isolated, and it has since been shown to have
numerous roles in both basal and stress granulopoiesis. G-CSF was purified from human
placental (26) or murine lung (27) conditioned medium on the basis of its ability to
stimulate the growth of granulocyte colonies from bone marrow cells. The murine (28)
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and human (29, 30) cDNA for G-CSF was subsequently cloned based on protein
sequence and species homology, and this enabled expression of recombinant protein and
other tools to further investigate the function of G-CSF. G-CSF expression is induced in
numerous different cell types upon stimulus with appropriate immunogenic factors such
as LPS, TNFα, INFγ, or IL-1β, which would be expected given the key role of G-CSF in
stimulating neutrophil production to help mount an appropriate immune response.
Transcription is initiated by the binding of NF-κB p60 and NF-IL6 at their binding sites
in the promoter region (31). G-CSF expressing cells include hematopoietic cells such as
monocytes, granulocytes, T lymphocytes, and macrophages as well as stromal cells,
fibroblasts, endothelial cells, and mesothelial cells (32). Most cells express very low
levels of basal G-CSF expression, although many tumor cells have constituitive
expression.
Consistent with this, at baseline there are low but detectable levels of serum GCSF that increase dramatically in response to infection along with an increase in the
circulating neutrophil count (33). G-CSF treatment causes neutrophilia (34-37) resulting
from increased proliferation of myeloid precursors and decreased transit time through the
post-mitotic compartment in the bone marrow (38-40). As a result, G-CSF is used
clinically to treat neutropenia and prevent infections. In vitro, G-CSF treatment
stimulates the proliferation of myeloid progenitors (41).
At the molecular level, the effects of G-CSF are mediated by signaling through
the G-CSF receptor (G-CSFR).

The G-CSFR is a member of the hematopoietic

cytokine receptor family and consists of single extracellular, transmembrane, and
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cytoplasmic domains. The N-terminal portion of the cytoplasmic domain binds and
activates JAK kinases, which phosphorylate tyrosines on the C-terminal portion of the
cytoplasmic tail and activate STAT proteins. Other signals are transmitted through the
RAS-ERK1/2 pathway and cytoplasmic kinases such as LYN and SYK. The main target
cells of G-CSF, hematopoietic stem cells, myeloid progenitor cells, and granulocytes and
their precursors, express the G-CSFR, and its expression is upregulated as the cells
mature (42). However, other hematopoietic and stromal cell types, including endothelial
cells (43), also express the GCSFR .
Genetic evidence that G-CSF signals are required for normal neutrophil
production was provided by the identification of rare, dominant negative mutations in the
G-CSFR in humans with severe congenital neutropenia (44-46). Conversely, a pedigree
with chronic neutrophilia and constitutively active G-CSFR mutations has also been
recently reported (47). A definitive role for G-CSF in controlling neutrophil production
was shown by studies in transgenic mice. Both G-CSF-deficient (CSF3-/-) (48) and GCSFR-deficient (CSF3R-/-) (49) mice exhibit a profound but not absolute neutropenia
along with reduced numbers of myeloid cells in the bone marrow. The evidence suggests
that G-CSF controls granulopoiesis through a number of different mechanisms. Early in
myeloid development, it is necessary for commitment of primitive progenitors to the
myeloid pathway (50). In CSF3-/- or CSF3R-/- mice, there is decreased proliferation of
myeloid progenitors and decreased survival as evidenced by increased susceptibility to
apoptosis (11). However, expression of a GCSFR engineered to contain a cytoplasmic
tail that was either truncated (D715) or replaced with the cytoplasmic tail of the
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erythropoietin receptor (GEPOR) showed that the distal portion of the GCSFR
cytoplasmic tail was dispensable for G-CSF induced granulocytic differentiation, but
required for other functions of G-CSF as discussed below (51, 52). Conversely, STAT3
activation mediated by JAK kinase attachment at the proximal cytoplasmic portion of the
G-CSFR upon ligand binding is required for normal myeloid cell proliferation and
neutrophil development (53). G-CSF signals are necessary for appropriate release of
neutrophils from the bone marrow into the blood under both basal and stress conditions
(discussed below). Lastly, G-CSF is important for neutrophils to function appropriately
in arriving at the site of infection and displaying bacteriocidal activity. Neutrophils
lacking a complete G-CSFR had impaired chemotaxis and adhesion molecule
upregulation (52, 54), while neutrophils from CSF3-/- mice had morphological defects,
impaired phagocytosis, and defective nitric oxide production (55). Additionally, G-CSF
treatment of wild-type neutrophils activates them and enhances phagocytosis, superoxide
anion generation, and bacterial killing (56).

1.3.3 Additional mechanisms
Several other factors that regulate neutrophil production deserve mention but will
not be covered in detail. Effective granulopoiesis requires proliferative signals from
cytokines, but these signals must be dampened by negative regulatory molecules within
the cell to prevent excessive production of neutrophils. It is important to note that
numerous other cytokines besides G-CSF have been shown to have a role in
granulopoiesis, including GM-CSF, M-CSF, IL-3, IL-6, IL-17, and IL-23 (57-62).
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Indeed, mice lacking G-CSF, GM-CSF, and M-CSF could still produce neutrophils (63),
showing that many compensatory pathways are likely to exist that are non-essential in the
presence of G-CSF (e.g. GM-CSF, IL-3, IL-6). Studies of mice with genetic alterations
in the signaling molecules STAT3 or SOCS3 showed that they were negative regulators
of G-CSF-induced neutrophil production that act by dampening G-CSF signaling (64,
65). Finally, given their rapid production and subsequent destruction and toxic granule
components, neutrophils must maintain tight control over apoptosis. The pro-apoptotic
molecule BIM and anti-apoptotic MCL-1 seem to be the key regulators of this process in
myeloid lineage cells including neutrophils (66, 67).

1.4

Regulation of neutrophil release

After neutrophil production in the bone marrow, a second regulatory checkpoint for
neutrophil homeostasis is the control of neutrophil egress from the bone marrow into the
circulation.

1.4.1

Bone marrow architecture and composition

Like all other blood cells, neutrophils are produced in the bone marrow hematopoietic
compartment, an extravascular space characterized by dense cords of hematopoietic
tissue. The bone marrow extracellular matrix (ECM) has a typical composition of
various types of collagen, proteoglycans, and glycoproteins (68). In order to enter the
circulation, neutrophils must transmigrate across a vascular barrier into venous sinuses
dispersed throughout the marrow cavity (69). As demonstrated by ultrastructural studies,
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the vascular wall of the venous sinus is physically made up of three layers: endothelial
cells, a basement membrane, and adventitial cells (Figure 1-2A-C) (70, 71). In some
places, the membranes of the endothelial cells are fused, forming openings known as
diaphragmed fenestra through which cells can cross into the circulation (71, 72). Thus,
migration across the endothelium occurs via a transcellular route, although passage
through the adventitial cell layer occurs via a paracellular route. This process, also
known as neutrophil mobilization, must be highly regulated since only mature neutrophils
of band or segmented nuclear morphology are released under basal conditions, despite
the enormous amount of neutrophils produced in the marrow space daily. In addition to
the endothelium-associated cells mentioned above, other stromal cells in the bone
marrow include adipocytes, macrophages and various osteoblast lineage cells (68).
Together, the ECM and various stromal cells are thought to form niches for
hematopoietic cells that regulate their development, function, and survival, but there is
limited knowledge about the specific molecules that might mediate these interactions.
Modulation of adhesive interactions with the ECM and stromal cells, chemotaxis
toward the endothelium, and transmigration across the vascular barrier must logically
occur for neutrophils to exit the bone marrow. The molecules known to be involved in
these processes are discussed below, and a major contribution of this thesis is to further
define the regulators of neutrophil egress from the bone marrow. Additional avenues of
investigation for defining additional molecules that play a role will be discussed in
Chapter 4.
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1.4.2

Neutrophil mobilization by G-CSF

Second, the regulatory mechanism is flexible enough to allow a dramatic and rapid
increase in the circulating neutrophil count in response to infection or other bodily stress
in a process termed “emergency granulopoiesis”. For example, under basal conditions,
only 1-2% of the total body neutrophils are present in the circulation, with a large portion
of the remainder held as a “ready reserve” in order to respond to infection or other acute
demand (73). However, after treatment with G-CSF, the release of neutrophils into the
blood increases so that the blood contains ~10% of the total neutrophils. Further
experiments showed that the release was dependent upon signals generated by the
membrane proximal portion of the G-CSFR acting in a non-cell intrinsic manner (74). GCSF treatment also acutely increases the circulating neutrophil count (36, 37), in sum
showing that G-CSF is a potent regulator of neutrophil release in addition to stimulating
neutrophil production.

1.4.3

Emergency granulopoiesis and mobilizing agents

Many diverse compounds can induce neutrophil release (or production) in addition to GCSF. It is important to note that neutrophil production and release are closely interrelated
processes that can be difficult to separate. In general, rapid responses are more
attributable to release since additional neutrophils have not been produced yet.
Furthermore, neutrophil production and release may be regulated by distinct mechanisms
under basal versus stress conditions. Emergency granulopoiesis may utilize multiple
pathways with additive or supplementary effects upon the basal regulatory machinery,
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while regulation under homeostatic conditions may be relatively less complex. However,
even without clinical infection, animals are constantly being exposed to bacteria,
indicating that basal versus stress processes likely are a continuum rather than two
distinct entities.
A stress granulopoiesis response is characterized by release of neutrophils from
the marrow in its early phase and supplemented by increased production of neutrophils
via increased myeloid progenitor commitment, increased cell cycling, and increased
immature myeloid cells in its later phase. Consistent with their biological function, a
neutrophil response can be elicited by bacterial infection. For example, granulopoiesis is
enhanced by intratracheal Escherichia coli infection (75). CSF3-/- mice fail to generate a
neutrophilia and have impaired clearance of intravenous Listeria monocytogenes
compared to wild type controls. However, with intraperitoneal infection CSF3-/- mice had
a normal neutrophilia but were still susceptible to infection (76). When infected with
Candida albicans, neutrophils were mobilized in a G-CSF, GM-CSF, and IL-6
independent manner (77). Neutrophil mobilization was impaired in CSF3R-/- mice
responding to pulmonary Pseudomonas aeruginosa infection (78). G-CSF signals seem
to be necessary for emergency granulopoiesis in some infections, but there are redundant
signals in other cases. In all cases, an increase in circulating neutrophils could be elicited
by administration of an infectious agent, and this increase was needed for effective
bacterial clearance.
Many other substances can also cause neutrophil release; they are generally in the
category of inflammatory mediators produced in response to infection, but there are
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examples outside of this paradigm as well. Classes of molecules include cytokines,
chemokines, leukotrienes, bacterial products, and complement factors. Specific examples
of agents that stimulate emergency granulopoiesis or neutrophil release include the
hematopoietic cytokines TNFα (79), TNFβ, G-CSF (36), GM-CSF (80), IL-1 (79), IL-3
(81), and IL-6 (82), the chemokine CXCL8 (IL-8) (83), leukotriene B4 (84), bacterial
endotoxin (LPS) (85), C5a (84), platelet activating factor (PAF) (84), the peptide Nformyl-met-leu-phe (fMLF) (84), prostaglandin analogues, epinephrine, corticosteroids,
and even lithium (86). Many of these agents have been documented to increase during
infection, and IL-6 (62) and GM-CSF (76) are required for appropriate resolution of
infection in experiments utilizing gene-deficient mice. The kinetics of these agents are
variable, with peak responses occurring anywhere from one to twelve hours after
treatment. This suggests that multiple pathways are involved that have several steps.
Indeed, one could envision that agents with delayed responses must induce secondary
mediators, while agents with more rapid responses may act more directly upon
neutrophils and be downstream steps in the pathway. Some of these agents, such as
CXCL8 or C5a, also activate neutrophils and direct their chemotaxis. Mice genetically
deficient for GM-CSF (87), IL-3 (88), or IL-6 (62) display normal hematopoiesis,
indicating that these cytokines are not required for basal granulopoiesis despite their
potential involvement in stress granulopoiesis. Conversely, mice deficient for both the
G-CSFR and IL-6 display neutropenia of greater severity than that of the CSF3R-/mouse, suggesting that IL-6 does play a role in basal granulopoiesis (89). Lastly, at least
one second messenger has been shown to be important in mediating neutrophil release.
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Mice deficient in STAT3, one of the main intracellular tranducers of G-CSF signals, are
unable to acutely mobilize neutrophils in response to G-CSF treatment, but have
increased basal levels of peripheral neutrophils (90). This suggests an inadequate reserve
of immature neutrophils in STAT3-/- mice and the possibility of distinct pathways
operating in basal versus acute neutrophil release. In sum, many pathways can lead to
neutrophilia. However, the steps that lead from elevation of an inflammatory mediator to
neutrophil release into the circulation are relatively unknown. The work presented in this
thesis supports the idea that chemokine signaling in the bone marrow is a common final
step mediating neutrophil trafficking from the bone marrow under both basal and stress
conditions. The current knowledge of mechanisms governing neutrophil release from the
bone marrow is summarized below.

1.4.4

Adhesion molecules

It is well known that adhesion molecules regulate the egress of leukocytes from the blood
into the tissues to arrive at sites of inflammation or immune surveillance (91-93). The
major adhesion molecules regulating neutrophils are integrins and selectins. Of note, a
considerable portion of the intravascular pool of neutrophils are marginated at the vessel
walls and thus not reflected in blood neutrophil counts; the marginated pool can
constitute up to one-half of the total intravascular pool (9). This pool can vary depending
on neutrophil activation state and be “mobilized” by certain stimuli.
Humans with leukocyte adhesion deficiency (LAD) exhibit neutrophilia and
increased susceptibility to infection secondary to impaired neutrophil migration into

17

tissues caused by genetic deficiency of β2-integrins (LAD I), selectin signaling (LAD II),
or downstream signaling molecules (LAD III) (5). A number of adhesion moleculedeficient mice have been generated, and they all exhibit increased circulating neutrophils,
reproducing the phenotype of LAD syndromes (5). These observations are consistent
with the requirement for the various classes of molecules at various steps of the leukocyte
adhesion cascade that regulates exit from the circulation. The neutrophilia in LAD mice
is invariably associated with elevated serum levels of IL-17, the key observation that
allowed elucidation of the homeostatic feedback loop described below (94). In β2integrin-deficient (ITGB2-/-) mice, neutrophil counts normalize with the addition of wildtype hematopoietic cells in bone marrow chimeras (94, 95). These studies together
showed that LAD neutrophilia is not caused by the passive accumulation of neutrophils
in the circulation or altered proliferation. Of note, neutrophil apoptosis is decreased in
ITGB2-/- mice but not in ITGB2-/- neutrophils from bone marrow chimeras that also
contain wild-type cells (96).
Recent investigations have focused on whether adhesion molecules could play a
role in the movement of neutrophils from the extravascular space of the bone marrow into
the circulation. This idea is supported by the fact that adhesion molecules are important
in regulating the survival and release of other cell populations in the bone marrow,
particularly hematopoietic stem cells (97). Mice carrying genetic deletions of these
molecules provide tools to test this hypothesis, but observations must be interpreted with
caution because these mice often have elevated white cell counts secondary to excessive
granulopoietic cytokine production (described below). Administration of blocking
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antibodies for CD18 (β2-integrins) or L-selectin had no effect on the neutrophilia induced
by C5a, TNFα, or fMLF (98). Using an in situ perfusion model to precisely measure
neutrophils mobilized from one femur in response to the chemokine CXCL2 (MIP-2),
Burdon et al assessed the effect of blocking or modulating the adhesion molecules CD18,
VLA-4 (α4β1 integrin), or L-selectin on mobilization. Their results suggested that CD18
retains neutrophils in the bone marrow, while VLA-4 plays an opposing role by
augmenting neutrophil release and L-selectin is dispensible (99).

Consistent with this,

irradiated mice reconstituted with a mixture of wild type and ITGB2-/- cells had increased
percentages of neutrophils in ITGB2-/- circulating leukocytes (95). However, another
group reports that there was no evidence for altered neutrophil mobilization in selectindeficient or ITGB2-/- - neutrophils in mixed bone marrow chimeras (5). No abnormalities
in neutrophil release have been described in α4-integrin (100) or L-selectin deficient mice
(101, 102). Finally, in contrast to the results obtained after mobilization by CXCL2,
Petty et al showed that blockade of VLA-4 or its receptor VCAM-1 resulted in increased
neutrophil mobilization that was augmented by CXCR4 inhibition (103). They also
suggested that CXCR4 stimulation increased VLA-4/VCAM-1 adhesion in a pertussis
toxin-dependent manner.
Thus, the data on the role of adhesion molecules in neutrophil mobilization are
contradictory and likely to be highly dependent on the details of the experimental system
employed. Clearly, further experiments must be performed to fully characterize the role
of adhesion molecules in the regulation of neutrophil release from the bone marrow.
Some adhesion molecules may play redundant roles. The cell-intrinsic role of these
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molecules has not been clearly defined in genetically deficient mice. CXCL2 is an
inflammatory chemokine important for neutrophil mobilization from the marrow and
homing to inflamed tissues, but in general the role of adhesion molecules in stress
granulopoiesis has not been characterized.

1.4.5

Neutrophil homeostatic feedback loops

Homeostatic negative feedback loops controlling circulating neutrophil numbers have
been suggested in the literature (95, 104), but no data to support them had been presented.
Recent work (94, 105, 106) provides evidence that IL-17 production by specialized Tcells stimulates G-CSF production, which in turn positively regulates granulopoiesis
(Figure 1-3). IL-17 production is positively regulated by IL-23 produced by
macrophages and dendritic cells in the gut. These cells decrease their production of IL23 upon phagocytosing apoptotic neutrophils, thus providing a way to match neutrophil
production with neutrophil clearance. Consistent with such a feedback loop, mice that
overexpress IL-17 or IL-23 are neutrophilic (60, 107), while the mice genetically
deficient for these cytokines or their receptors are neutropenic and/or have impaired
neutrophil responses to stress or infection (59, 106, 108). Bone marrow transplant
experiments subsequently confirmed that hematopoietic cells are the source of IL-23
(107), while the cells that respond to IL-17 and produce G-CSF in vivo are nonhematopoietic stromal cells (108). An earlier report had demonstrated that IL-17 could
stimulate the production of G-CSF, IL-6, CXCL8, and prostaglandin E2 (PGE2) in
epithelial, endothelial, and fibroblastic cells in vitro (109). It is not yet clear how this
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negative feedback loop becomes a positive feedback loop during infectious conditions, as
the number of neutrophils in the tissues is increased, yet G-CSF production and
subsequent granulocyte proliferation and mobilization into the blood remain elevated for
the duration of the infectious episode. However, IL-17 signaling is required for an
effective innate immune response in murine models of Toxoplasma gondii or Klebsiella
pneumoniae infection, as mice deficient in the receptor for IL-17 (IL-17RA-/-) mice had
decreased survival (59, 110).

1.4.6

Cell biology of neutrophil mobilization by G-CSF

As discussed above, the GCSFR is expressed primarily on hematopoietic cells but also on
some stromal cell types (42, 43). These data suggest that G-CSF may act on either
stromal cells or hematopoietic cells to induce neutrophil mobilization. Work by Dr.
Craig Semerad in our laboratory utilized a series of bone marrow radiation chimeras
derived from wild-type and CSF3R-/- mice to demonstrate that G-CSFR signaling in
hematopoietic but not stromal cells is necessary to induce neutrophil mobilization from
the bone marrow to the blood (74) (Figure 1-4A). The G-CSFR is highly expressed on
neutrophils; thus, it was expected that G-CSF signals acting directly on neutrophils would
lead to their mobilization in a cell-intrinsic manner. However, mice reconstituted with a
mixture of wild-type and G-CSFR-/- cells showed that this was not the case, as neutrophil
release at baseline or in response to G-CSF was equivalent between the two genotypes
(Figure 1-4B). Of note, the number of wild-type neutrophils in the bone marrow of the
mixed chimeras was nearly equal to the number in control chimeras transplanted with
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wild-type cells alone because of the defects in neutrophil production in G-CSFR-deficient
cells. These data show that G-CSF signals in neutrophils were neither necessary nor
sufficient for their mobilization and suggest the presence of indirect, trans-acting signals
generated by G-CSF signaling in a non-neutrophilic hematopoietic intermediary. Two
such potential signals are discussed below: proteases and CXCL12.

1.4.7

Neutrophil proteases

Neutrophils contain an array of proteases in their granules; these enzymes allow the
neutrophil to degrade tissue and cellular debris at a site of inflammation and thereby
contribute to the resolution of an infection. A recent hypothesis proposes that these same
proteases can mediate neutrophil and/or hematopoietic stem cell mobilization from the
bone marrow by cleaving signaling, adhesion, or extracellular matrix proteins. Evidence
for this hypothesis shows that G-CSF treatment results in increased expression of the
neutrophil serine proteases cathepsin G (CG) and neutrophil elastase (NE) (111).
Furthermore, these proteases were able to cleave VCAM-1 (112), c-Kit (113), CXCL12
(SDF-1), and its receptor CXCR4 (114), which are all molecules thought to be important
for regulating neutrophil or stem cell release from the marrow. Neutrophil mobilization
by CXCL8 (IL-8) was impaired by neutralizing antibodies against MMP-9 (115).
However, mice genetically deficient for the proteases MMP-9, both CG and NE, or DPPI
all had normal resting neutrophil counts and normal mobilization after G-CSF treatment.
This result was confirmed by pharmacologic inhibition of a broad spectrum of
metalloproteinases in DPPI-deficient (CTSC-/-) mice, which lack the enzyme necessary
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for the activation of all neutrophil serine proteases (116). Together, this data shows that
proteases are not necessary for neutrophil mobilization, or at least not mobilization by GCSF. It is possible that different mobilizing agents utilize distinct mechanisms, that
redundant mobilization pathways are involved, or that unknown proteases can provide a
compensatory function.

1.4.8

The CXCR4/CXCL12 axis provides a key retention signal

Accumulating evidence suggests that signaling through the CXC-chemokine receptor 4
(CXCR4) induced by its ligand, stromal-derived factor-1 (SDF-1 or CXCL12) provides a
key retention signal regulating neutrophil release from the bone marrow. The molecular
and cellular biology of CXCR4 will be discussed further below. In brief, CXCR4 is
broadly expressed on hematopoietic cells, and CXCL12 is constitutively produced in the
bone marrow compartment by distinct types of stromal cells as discussed below (Figure
1-2D) (117, 118). Mice reconstituted with CXCR4-/- cells have impaired retention of
granulocytes in their bone marrow and increased circulating neutrophils (119).
AMD3100, specific antagonist of CXCR4 signaling, induces an increase in circulating
neutrophils in mice and humans (120, 121). Patients with WHIM syndrome, a disease
characterized by mutations in CXCR4 that confer elevated sensitivity to CXCL12, have a
severe neutropenia (122, 123). G-CSF induced neutrophil mobilization is accompanied
by a decrease in bone marrow CXCR4 and CXCL12 levels (74, 124, 125) (Figure 1-3
and 1-5). Using a series of G-CSFR mutant mice that have varying degrees of neutrophil
mobilization in response to G-CSF treatment, our laboratory has shown that the
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magnitude of the CXCL12 decrease is inversely correlated with mobilization (74).
Although these data convincingly demonstrate that CXCR4 signals play a role in
neutrophil homeostasis, the precise manner in which it acts to regulate neutrophils is
undefined. The specific role of CXCR4 in neutrophil homeostasis is defined in Chapter
2 of this thesis using mice with a myeloid-specific deletion of CXCR4.

1.4.9

Regulation of CXCL12 production in the bone marrow by G-CSF

CXCL12 is produced in non-hematopoietic bone marrow stromal cells that include
osteoblast lineage cells, endothelial cells, fibroblasts, and other cell types (118). The
normal phenotype in irradiated wild-type mice reconstituted with CXCL12-/- cells
confirmed that non-hematopoietic stromal cells are the source of the biologically
important CXCL12 (126). A number of authors have attempted to define the biologically
important population of CXCL12-producing cells in the bone marrow (127-130). They
show that endothelial cells, osteoblasts, and associated reticular cells all may play a role
in regulating CXCL12 (Figure 1-2D). Work by Dr. Semerad and Dr. Matthew
Christopher in our laboratory identified osteoblasts as the major producers of CXCL12
within the bone marrow stromal cell compartment and showed that G-CSF or other
cytokines downregulate CXCL12 secondary to suppression of osteoblast number (131133). However, the bone marrow chimera data discussed above suggest that G-CSF does
not act directly on osteoblasts. Instead, the sum of the data suggest a model for neutropil
mobilization where G-CSF signaling in a subset of hematopoietic cells generates
secondary signals that act in trans to suppress osteoblasts and CXCL12 expression
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(Figure 1-5). Recent, unpublished work by Dr. Christopher and others suggests that
monocytes are the key subset of hematopoietic cells upon which G-CSF acts. The nature
of the secondary signals, effects of G-CSF on other stromal cell populations, and
potential additonal (chemokine or non-chemokine) molecules important for neutrophil
mobilization produced by (osteoblast or non-osteoblast) stromal cells need to be
determined and are areas of active investigation in our laboratory. Specifically,
endothelial cells are capable of producing a wide variety of chemokines, but data on the
properties of bone marrow endothelium are limited, as most studies have focused on
activated endothelium in vitro or in other tissues. Work presented in Chapter 3 of this
thesis will address some of these questions.

1.5

Regulation of neutrophil clearance

A final regulatory step in controlling neutrophil counts is the process of neutrophil
margination and extravasation into the tissues. The cellular and molecular signals
necessary for the process of neutrophil arrest on the endothelium, adherence, and
transmigration across the vascular barrier from the blood to tissue sites of inflammation
have been well described (91, 92) and will not be covered here. Another aspect of
neutrophil clearance is the investigation of where and how neutrophils are cleared under
homeostatic conditions. Neutrophils home to many different tissues, with the most
prominent being the bone marrow, spleen, and liver (134). These senescent neutrophils
presumably undergo apoptosis and are cleared by tissue macrophages at these sites (135).
The kinetics of clearance are rapid, with a calculated blood half life of 3-11 hours
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depending upon the method of measurement used. Neutrophil clearance does not depend
upon G-CSF signals, as neutrophils in CSF3-/- mice have a normal half-life (11), as did
mice expressing the chimeric GEPOR (74). Conversely, recent data suggests that in
addition to its role regulating neutrophil release, CXCR4 may play a role in neutrophil
clearance at bone marrow sites. CXCR4 is upregulated as neutrophils age in vitro (121,
136, 137). CXCR4high neutrophils preferentially home to the bone marrow, and this
homing is abrogated by blocking antibodies against CXCR4 (121, 138). CXCL12
stimulation of CXCR4 induces TNF related apoptosis inducing ligand (TRAIL) and
TRAIL receptors that increase the sensitivity of neutrophils to apoptosis (139). Together,
these data suggest that CXCR4 regulates not only neutrophil release, but neutrophil
clearance and apoptosis as well. However, these results must be interpreted with caution,
as the ex vivo manipulation necessary for these experiments can activate neutrophils and
alter their homing and apoptosis. In Chapter 2, we demonstrate that CXCR4 mediates
neutrophil homing to the bone marrow but it is not essential for the clearance of
circulating neutrophils.

1.6

Chemokines and regulation of neutrophil release

1.6.1

The Chemokine System

The name chemokine is a combination of the words chemotactic cytokine, and the
classically described function of chemokines is indeed to direct the chemotaxis of various
leukocyte subsets and thereby regulate their trafficking throughout the body.
Chemokines are soluble proteins that form chemotactic gradients, and they are produced
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by a variety of cell types. They bind to specific receptors on the cell surface, which are
all seven-transmembrane proteins that signal by activating heterotrimeric G proteins
through exchange of GDP for GTP. They can be classified into inducible or homeostatic
groups, with the former being important for inflammatory responses and the latter being
important for immune cell surveillance and developmental functions. The accepted
nomenclature for chemokines is based on the presence of a C-C, C-X-C, C-X3-C, or C-X
amino acid motif, and they are numbered in the order of their discovery (140).
Chemokine receptors are named similarly according to the class of chemokine they bind
(141). Chemokines and their receptors are implicated in the pathogenesis of numerous
diseases with an infectious or inflammatory component, including cancer cell survival
and metastasis (142), and have therefore been well-studied as drug targets (143).

1.6.2

CXCR4/CXCL12

CXCR4 (reviewed by Busillo and Benovic (144)) was originally discovered for its role as
a coreceptor required for HIV-1 entry into cells, and its major ligand CXCL12 (SDF-1)
was identified by its ability to block viral entry (145-147). CXCL12 had previously been
cloned from a bone marrow stromal cell line and was noted for its role in promoting B
lymphocyte development. CXCR4 and CXCL12 are among the most well-studied and
unique chemokine ligand-receptor pairs. They have a diverse array of functions in
addition to directing leukocyte trafficking. CXCL12 and CXCR4 are expressed in many
sites throughout the body, including brain, thymus, heart, lung, liver, lymph node, kidney,
spleen, stomach, intestine, and bone marrow. As mentioned above, considerable interest
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has been directed at defining the cell type within the bone marrow that expresses the
CXCL12 important for regulating leukocyte and stem cell function. Several studies have
provided somewhat conflicting results, but in general CXCL12 expression is localized to
sites near the endothelium or endosteum (Figure 1-2D) (103, 127-129, 131). CXCR4 is
present in every mature leukocyte type in addition to being expressed in more primitive
hematopoietic cells (148). Therefore, CXCR4 has been widely studied for its role in
directing hematopoietic stem cell migration, a process of critical importance for the
treatment of malignancy with stem cell transplant. In addition to its role in HIV
infection, CXCR4 has been implicated in the development and metastasis of various
cancers of hematopoietic, epithelial, and neural origin (149). Lastly, in an atypical
function for chemokines, CXCL12 or CXCR4 is required for the appropriate
development of the cerebellum, cardiac septum, gut vasculature, in addition to being
necessary for development of B lymphopoiesis and myelopoiesis in the hematopoietic
system.
In perhaps another indicator of their distinct properties compared to most
chemokines, both CXCR4 and CXCL12 are highly evolutionarily conserved. The murine
and human orthologues of CXCL12 have 99% homology, while the CXCR4 gene is 90%
conserved between the two species. This is in contrast to the much lower homology of
chemokines CCL2 (MCP-1) (55%), CCL3 (MIP-1α) (75%), or the CXCR2 receptor
(71%). Additionally, CXCL12 has a chromosomal location on 10q distinct from the C-XC chemokine cluster on 4q. It is constitutively expressed in many tissues, while most
other chemokines show inducible expression. CXCR4 is located on chromosome 2q near
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other chemokine receptor genes. CXCL12 is thought to be the major physiologic ligand
for CXCR4 because of their nearly identical tissue expression pattern and the fact that
CXCL12-/- and CXCR4-/- mice have nearly identical phenotypes (150). However,
additional receptors and ligands have since been described (see below).
The transcriptional expression of CXCR4 is regulated by a number of factors.
Importantly for this work, CXCR4 is expressed on neutrophils (136, 138) and
downregulated by the cytokiness IFN, GM-CSF, and G-CSF in vitro and in vivo (124,
136). G-CSF treatment negatively regulates the transcription of CXCR4 by inducing the
expression of the late myeloid transcription factor GFI-1(151). If mature neutrophils are
shutting off their transcription of CXCR4, this may explain why bone marrow neutrophils
have the highest CXCR4 expression and peritoneal neutrophils the lowest, with blood
neutrophils intermediate (138). Conversely, other studies have shown that CXCR4 is
upregulated as neutrophils are aged in vitro (121, 137) Other neutrophil releasing factors
such as LPS (152) and lithium(153) have also been shown to downregulate CXCR4
mRNA in neutrophils in vitro. Transcriptional downregulation of CXCR4 by neutrophil
mobilizing agents or with maturation may contribute to neutrophil release, consistent
with the idea of CXCR4 as a retention signal. However, the role of CXCR4 in the
clearance of aged, senescent neutrophils is not clear. This question will be addressed in
Chapter 2.
The mechanisms of CXCR4 trafficking to the cell membrane, signal transduction,
desensitization, internalization, and degradation generally follow those described for
GPCRs in general and are covered in the review above (Figure 1-6) (144). However, a
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few points merit mention. CXCR4 exists and signals as a dimer on the cell membrane,
transmitting signals via heterotrimeric G-proteins with a Gαi subunit. It has also been
shown to signal via JAK proteins and binding of β-arrestin molecules. CXCR4 is
degraded by agonist-induced ubiquitination by the E3 ligase AIP4 and sorting to the
lysosome. Additionally, its signaling upon CXCL12 binding can be desensitized by
phosphorylation of residues on the cytoplasmic tail by G-protein receptor kinases
(GRKs). Some of these phosphorylated residues allow binding of β-arrestins, which then
mediate receptor internalization. Interestingly, in B and T lymphocytes from mice
deficient in GRK6 or β-arrestin-2, membrane GTPase activity was increased but
chemotaxis was severely impaired, indicating that chemotaxis in these cells was Gprotein independent but dependent on β-arrestin binding to the receptor (154). However,
GRK6-/- neutrophils had increased chemotaxis toward CXCL12 and impaired G-CSFinduced neutrophil mobilization, but normal basal neutrophil counts (155). This finding
was supported by the fact that CXCR4 lacking the entire cytoplasmic tail had impaired
desensitization and internalization (156). However, the cytoplasmic tail was required for
chemotaxis, indicating that it has important signaling functions in addition to regulating
internalization. Desensitization and downregulation of CXCR4 through phosphorylation
of the cytoplasmic tail by GRKs are likely to be important in regulating neutrophil
release.
CXCR4 signaling has diverse functions in numerous organ systems. Mice
genetically deficient in either CXCL12 or CXCR4 die perinatally (embryonic day 18.5 to
~1 hour after birth) and display defective cerebellar granule cell formation, ventricular
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septal defects, impaired blood vessel formation, and a failure to establish definitive B
lymphopoiesis and myelopoiesis in the bone marrow (150, 157-159). The role of
CXCR4 signals in brain development was a novel finding, and it fits nicely with the role
of CXCR4 as a proliferative signal in pediatric brain tumors (160). Further studies
showed that CXCR4 was the only chemokine receptor expressed during embryogenesis,
and that it signaled during gastrulation (161). Studies with radiation chimeras and further
analysis of knockout mice confirmed CXCR4/CXCL12 signaling to have a major role in
early B lymphopoiesis (162), T lymphocyte repopulation and development in the thymus
(163), and retention of B lymphocytes and neutrophils in the bone marrow (119).
CXCR4-/- but not CXCL12-/- hematopoietic stem cells (HSC) exhibit an engraftment
defect in repopulating irradiated mice, indicating that CXCL12 is produced by nonhematopoietic cells while CXCR4 is required on hematopoietic cells (126). In agreement
with this finding, studies of human HSC treated with blocking antibodies for CXCR4
showed impaired NOD-SCID engraftment (164). Additionally, through studies primarily
in human HSC, CXCR4 signals were shown to regulate cell adhesion (165), survival
(166), and proliferation (167) in addition to the cell migration defects apparent from
studies of knockout mice. Interestingly, the defect in bone-marrow colonization by long
term HSCs in CXCL12-/- embryos can be rescued by endothelial cell expression of
CXCL12, but the reduction in myeloid cells remained (168). This suggests that some
other cell type in the bone marrow produces the CXCL12 important for neutrophil
retention in the bone marrow, possibly osteoblasts as mentioned above.
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Precise control of the level of CXCR4 signaling may be necessary for the
appropriate chemotaxis or migration of cells. In a zebrafish model, it has been
demonstrated that CXCR4 is essential for appropriate germ cell migration to their target
during development (169). However, when a truncated CXCR4 protein that was
defective in internalization and thus had an elevated level of signaling was expressed in
CXCR4 deficient zebrafish embryos, the germ cells failed to arrive at the gonad despite
normal motility and directional sensing (170). This demonstrates that subtle alterations
in CXCR4 signaling can affect cell migration in vivo.

1.6.3

Additional receptors and ligands: CXCR7 and MIF

Recently, an additional receptor (RDC-1) for CXCL12 has been identified. It was
subsequently classified as CXCR7, and it also binds CXCL11 (171). CXCR7 is
expressed on a specific subsets of T and B lymphocytes, endothelial cells, in fetal liver,
and on many tumor cell lines. Consistent with this, its expression in tumors provides a
growth advantage (172). It is a non-signaling receptor, unable to induce chemotaxis or
calcium transients in response to SDF-1. However, it can form oligomers with CXCR4,
and it augments CXCR4 signaling as demonstrated by additive effects of blocking
CXCR4 and CXCR7 in cells co-expressing the receptors (173). CXCR7-/- mice have
been described, and they have normal hematopoiesis, CNS, and gut vasculature but die
perinatally of severe heart valve defects (174). Knockdown of CXCR7 in zebrafish also
leads to vascular defects (172). In the zebrafish model of germ cell migration,
knockdown of CXCR7 leads to aberrant migration, and the authors conclude that CXCR7
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regulates CXCL12 gradients by acting as a sink, thus decreasing CXCL12 levels (175).
It is interesting to speculate that CXCR7 may act to regulate CXCL12 levels in the bone
marrow or CXCR4 sensitivity on neutrophils, thus fine-tuning CXCL12 gradients and
regulating neutrophil release during stress granulopoiesis.
Macrophage migration inhibitory factor (MIF) has recently been identified as a
ligand for both CXCR2 and CXCR4, and it played a role in T lymphocyte and monocyte
recruitment into atherosclerotic plaques (176). It is unclear what role it might have in
neutrophil mobilization.

1.6.4

CXCR2

It is not clear how modulation of neutrophil CXCR4 signaling is linked to their migration
toward the vascular endothelium and subsequent entry into the circulation. Therefore, the
question of whether neutrophil egress from the bone marrow is a passive, random process
or actively directed and what (if any) signals regulate it remains unanswered. Based on
their well-characterized role in other aspects of neutrophil biology, we hypothesized that
ELR+ CXC chemokines (CXCL1-3, 5-8), signaling through CXCR1 and CXCR2, oppose
CXCL12 and direct neutrophil release from the bone marrow (141, 177). This hypothesis
was tested in experiments described in Chapter 3 of this thesis.
Consistent with this idea, as immature Linlo Kit+ Sca+ (LKS) murine
hematopoietic cells were differentiated in vitro into mature neutrophils, they upregulated
CXCR2 expression (178). CXCR2 ligands are also potent neutrophil mobilizing agents.
Treatment of mice with CXCR2 ligands human CXCL2 (GROβ (179), CXCL8 (IL-8)
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(83), murine CXCL2 (MIP-2) (99), or CXCL1 (KC) (138) results in a rapid neutrophilia
that peaks at ~1 hour and resolves in 2-3 hours. However, it is not clear from these
experiments whether CXCR2 signaling plays a role in basal release or how these agents
mediate their effects within the bone marrow compartment.
It is important to realize that humans have two receptors, CXCR1 and CXCR2,
for CXCL8 (IL-8), the prototypic ELR+ chemokine. Both receptors are expressed on
myeloid cells (177), and the best described functions of CXCR2 and its ligands are
granulocyte and monocyte/macrophage specific. ELR+ chemokines induce neutrophil
accumulation at inflammatory sites by mediating a variety of steps in the process,
including expression of adhesion molecules, transmigration across the endothelium, and
release of proteases (141, 177). Of note, there is only one functional IL-8 receptor in the
murine genome, named CXCR2 because it has greater homology to human CXCR2 than
CXCR1 (68% vs 71%) (180). However, CXCR2 is also expressed in B lymphocytes,
consistent with the B cell expansion observed in CXCR2-/- mice (181). Additionally,
CXCR2 has been described to play a role in the proliferation of hematopoietic
progenitors, mediation of cellular senescence, wound healing, and angiogenesis through
its expression on endothelial cells (182-186).
ELR+ CXC chemokines are classically produced in autocrine fashion by myeloid
and endothelial cells to mediate leukocyte infiltration into inflamed tissue, but the
expression of ELR+ chemokines in the bone marrow is poorly characterized. CXCL2 is
produced by a subset of Gr-1+ cells in the bone marrow (187), but we did not observe
CXCL2 mRNA in F4/80+ monocytes under basal or stress conditions (unpublished
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observation). Parathyroid hormone-stimulated osteoblasts were recently shown to
produce CXCL1 (188).
Surprisingly, CXCR2-/- mice were first described to have a profound neutrophilia
with a myeloid and B lymphoid expansion in the bone marrow, spleen, and lymph nodes,
arguing against CXCR2 as a positive regulator of neutrophil release (189). However,
CXCR2-/- mice housed in a germ-free facility have normal hematopoiesis with normal to
decreased circulating leukocyte counts (183, 190, 191). CXCR2-/- neutrophils exhibited
defective emigration into sites of inflammation as expected. Taken together, these data
suggest that chronic subclinical infection and the systemic release of cytokines that
stimulate granulopoiesis are responsible for the unexpected phenotype in CXCR2-/- mice,
although a negative regulatory role for CXCR2 in myeloid progenitors has also been
proposed (183). It is also possible that CXCR2 signals are required for the neutrophil
emigration into peripheral tissues and/or clearance by phagocytes necessary to complete
the homeostatic feedback loop previously described (Section 1.4.5, Figure 1-3). Of note,
the phenotype of CXCR2-/- mice is very similar to humans or mice with LAD (190).
CXCR2 mutations have also been recently described in patients with familial
myelokathexis (discussed below). A bovine CXCR2 non-synonymous polymorphism that
impaired receptor function was associated with increased mastitis, but neutrophil counts
were not altered (192). Despite the common features of increased infection and altered
neutrophil homeostasis in the presence of these genetic alterations, the extent to which
the mechanism of dysregulation is shared is not clear.
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CXCR2 may interact with G-CSF signals to regulate neutrophil mobilization. GCSF treatment increases CXCR2 expression on neutrophils (193), and G-CSFR-deficient
neutrophils treated with CXCL8 have a number of impaired responses including lack of
mobilization (89). Neutrophils lacking STAT3, a key transducer of G-CSFR signals, or
those with a G-CSFR engineered to transduce EPOR-specific signals both had reduced
mobilization after G-CSF administration (74, 90). However, only STAT3-/- cells also
displayed impaired responses to CXCL2.
CXCR2 may regulate CXCR4 signaling and thereby regulate neutrophil release
through heterologous interactions. CXCR4 has been reported to undergo heterologous
desensitization in response to CXCR2 stimulation (138), but another report suggests that
CXCR1 but not CXCR2 mediates this effect (194). Modulation of CXCR4 signaling by
heteroligmerization with other chemokine receptors has been described, although not for
CXCR2 in particular (174, 195). Another recent paper showed that G-CSF, acting in a
CXCR4 dependent manner, cooperated with CXCL1 and CXCL2 to induce neutrophil
release from the bone marrow (196). However, this does not distinguish whether CXCR2
is cooperating by further abrogating CXCR4 signaling or by migrating toward the
chemotactic gradient of its own ligand. An alternative but not mutally exclusive
mechanism for neutrophil mobilization could act by fine modulation of the chemokine
gradients for CXCR4 and CXCR2 in the bone marrow to determine the relative balance
of neutrophil retention and release. It remains unknown what chemokines or other
mediators, besides CXCL12, would be important for this process and what cell types
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within the bone marrow produce these molecules. Bone marrow chemokine production
by stromal cells will be investigated in Chapter 3.
CXCR2 plays an important role in scavenging ELR+ chemokines. Scavenger
receptors could alter plasma chemokine levels and thus regulate neutrophil mobilization.
Accordingly, CXCR2-/- mice had elevated levels of CXCL1 (KC) and CXCL2 (MIP-2)
(197). Furthermore, in transgenic mice overexpressing CXCL1, CXCR2 signaling and
responses actually decreased because of receptor desensitization and downregulation in
response to excessive ligand (198).
As mentioned above, African-Americans have significantly lower neutrophil
counts, on average, than other ethnic groups (Figure 1-1A). “Benign ethnic neutropenia”
is also found in up to 5% of this population and defined as a neutrophil count < 1.5 x
109/L (199). Recently, genome wide association studies have implicated an inactivating
polymorphism in the duffy antigen receptor (DARC) on red blood cells in this condition
(200). DARC is a non-signaling chemokine receptor that acts as a chemokine sink (201).
It can bind CXCL8 and has been shown to alter plasma levels of chemokines important in
neutrophil homeostasis (202, 203).
It is unclear how CXCR2 would regulate neutrophil release. Does it interact with
CXCR4? Does it act in a cell-intrinsic fashion or generate trans-acting signals as in the
case of G-CSFR? What ELR+ chemokine ligands for CXCR2 are important for
neutrophil mobilization? Does it act during both basal and stress granulopoiesis? These
questions will be addressed Chapter 3.
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1.7 WHIM Syndrome
WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) syndrome
(reviewed by Diaz and Gulino (204)) is a rare disorder characterized by immune
dysfunction and neutropenia, first described by Zuelzer (205). Patients with the disorder
experience recurrent bacterial infections and extensive verrucosis secondary to chronic
human papillomavirus (HPV) infection (122). The number of neutrophils in the
peripheral blood increases during the response to infection or with G-CSF treatment,
suggesting that the defect in granulopoiesis is not absolute. Despite the peripheral
neutropenia, there are bizarre but mature neutrophils found in abundance in the marrow
of these patients (termed myelokathexis). Accelerated neutrophil apoptosis has been
reported in patients with myelokathexis as a potential mechanism of disease (206-208).
WHIM syndrome is a genetically and clinically heterogenous disease, ranging
from isolated myelokathexis to the full phenotype. The majority of reported cases have
an autosomal dominant inheritance pattern, while some sporadic (209, 210) or apparently
autosomal recessive cases have been reported. Truncating mutations in the cytoplasmic
(carboxy-terminal) tail of the CXCR4 gene located on chromosome 2q21 have been
identified the majority of patients tested to date, while 3 patients have a wild-type CXCR4
open reading frame (123, 210). One patient has been reported with isolated
myelokathexis who carries a CXCR4 mutation (123). As mentioned above, CXCR4 and
CXCL12 are essential for the appropriate development of B lymphocytes and myeloid
cells, the same cell lineages that are affected in WHIM syndrome. The mutations found
in patients with WHIM syndrome truncate 19 (1000CàT, R334X), 17 (1006G>T,
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G336X), 15 (1013CàG, S338X),13 (1016-1017delCT, S339fs342X), or 10 (1027GàT,
E343X) residues from the 46 amino acids of the cytoplasmic tail of the CXCR4 receptor,
with the R334X mutation being the most common (123, 210, 211).
Clinically, patients can also display variable lymphopenia and are subject to a risk
of malignancy related to viral infection. Two cases of B cell lymphoma, one of which
was Epstein-Barr virus (EBV) related, and several cases of cervical dysplasia related to
the common HPV serotypes 16 and 18 have been reported (209, 212-214). Patients have
an increased risk of congenital heart defects (7% vs. 0.8%), and there have been two
reports of patients with brain tumors, one patient with skeletal abnormalities, one patient
with recurrent herpes simplex virus infection (HSV) (204). Again, this spectrum of organ
system involvement fits nicely with the known defects in CXCR4-, CXCR7-, or
CXCL12- deficient mice. Overall, mortality from WHIM syndrome is low but it carries
significant morbidity; in the literature, one patient has died of sepsis, one from EBVrelated lymphoma, and one from glioblastoma. For example, one middle aged patient
was reported to have been hospitalized for severe infectious episodes over 80 times (215,
216).
CXCR4 constructs lacking the cytoplasmic tail have been shown to enhance
production of inositol phosphate, prolong ligand-stimulated release of intracellular
calcium, and decrease CXCL12-induced internalization while cell-surface expression and
CXCL12 binding remains normal (156). A cell line expressing the R334X mutation
showed increased calcium flux and chemotaxis in response to CXCL12, suggesting
abnormal, gain-of-function signaling by the mutant receptor (123, 217). The autosomal
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dominant inheritance pattern of WHIM syndrome also suggests a gain-of-function
mutation. In patient samples normal cell surface expression of CXCR4 and increased
leukocyte chemotaxis to CXCL12 was observed. Several reports suggest that impaired
CXCL12-induced CXCR4 internalization and desensitization acting in a dominant
negative manner could be responsible for the altered response to CXCL12 and the
clinical abnormalities (210, 218). However, another group reports no impaired
internalization or increased calcium flux in patient cells (211). If WHIM mutations do
cause CXCR4 internalization and desensitization defects, presumably it is due to lack of
phosphorylation sites for GRKs and subsequently impaired β-arrestin binding. Viral
expression of the R334X mutant in human CD34+ cells followed by transplant into
NOD-SCID mice led to impaired neutrophil release in vivo (219). Because CXCR4 has
been implicated in regulation of cell survival, other investigators have suggested that the
gain-of-function signaling may lead to increased neutrophil apoptosis (206).

1.7.1

Wild-type CXCR4 in WHIM syndrome patients

A puzzling and intriguing aspect of WHIM syndrome is the identification of patients with
the full clinical phenotype and impaired desensitization and internalization of CXCR4
who nonetheless have no CXCR4 mutations (210). This suggested the possibility of
alterations in molecules that regulate CXCR4 expression and function. This possibility
was confirmed in a recent report that demonstrated that impaired GRK3 production or
function played a key role in mediating increased CXCR4 signaling in patients with
WHIM syndrome (220). However, no mutations in GRK3 were present, suggesting that
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alterations in GRK3 a binding partner or other gene silencing mechanisms exist in these
patients. In contrast to data in mice indicating that GRK6 and β-Arrestin regulate
CXCR4 signaling in neutrophils (155), GRK6 and β-Arrestin function appeared to be
normal in these patients. Of note, GRK3 is highly expressed in normal leukocytes
including neutrophils (221). GRK3-/- mice exist (222), but there is no analysis of their
hematopoiesis in the literature.
The potential basis of disease in a second family with autosomal recessive
isolated myelokathexis (123, 215) and a wild-type CXCR4 gene has recently been
brought to our attention by our collaborator Dr. George A. Diaz (O’Shaughnessy, A.L.,
Sun, Q., Diaz, G.A., manuscript in preparation). These patients carry homozygous
968delA mutations in CXCR2 (IL8Rβ), a chemokine receptor specifically expressed on
neutrophils. The mutation results in H323fs6X truncation of the carboxy terminal
cytoplasmic tail of the receptor. However, the consequences of this truncation mutation
are quite different than for CXCR4 truncation mutations. The CXCR2 mutation results in
the loss of a F-X6-IL motif that is conserved in many GPCRs and required for export
from the endoplasmic reticulum (223). When expressed in cell lines, the mutant CXCR2
appears to be functionally null. There is no cell surface expression, and
immunofluorescence experiments showed accumulation of the protein in the endoplasmic
reticulum. The effect of this mutation in vivo or studies of patient leukocytes were not
reported. It is unclear how CXCR2 interacts with CXCR4 to regulate neutrophil release,
or how loss of CXCR2 signals could lead to disease in these patients. These questions
will be addressed in Chapter 3.
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Figure 1-1. Neutrophil counts and mortality. Cumulative incidence of neutrophil
counts in a sample of (A) 25,000 US Americans separated by race or (B) different inbred
strains of mice (n = 15-30 per strain). (C) Relationship between mortality and white
blood cell count (WBC). The dashed lines represent the 95% confidence interval.
Modified from von Vietinghoff and Ley (5) and Ruggiero et al (7). Panel A and B:
Copyright 2008. The American Association of Immunologists, Inc. Panel C reprinted
with permission from the American College of Cardiology. Mouse data originally
obtained from The Jackson Laboratory Mouse Phenome Database at
www.jax.org/phenome.
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Figure 1-2. Microanatomy of the bone marrow vasculature. (A) Schematic diagram
of the trilaminar structure of the bone marrow sinus wall showing the discontinuous
adventitial cell and basal membrane layers and the endothelium with openings known as
diaphragmed fenestrae (DF). (B) Electron micrographs demonstrating the passage of
neutrophils (arrow) though endothelial cells (arrowheads) and into the lumen of the bone
marrow venous sinus. (C) Fetal bone marrow endothelium shown by CD31 (PECAM-1)
staining demonstrates the normal pattern of blood vessels into which neutrophils
produced in the extravascular space must migrate. The dashed line shows the
approximate location of the endosteum. (D) Co-localization of some CD31+ cells with
CXCL12 (SDF-1) producing cells in fetal bone marrow. Modified from Petrides and
Dittman (panel A) (68), Furze and Rankin (panel B) (224), and Ara et al (panels C and
D) (168). Reprinted with permission from Elsevier.
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Figure 1-3. Homeostatic control of neutrophils via a feedback loop involving
cytokines and chemokines. See text for further details. In brief, tissue macrophages
and dendritic cells phagocytose transmigrated neutrophils, which downregulates their
constitutive production of IL-23. IL-23 stimulates production of IL-17 by T lymphocyte
subsets, which in turn positively regulates serum G-CSF levels. G-CSF induces
neutrophil release by down regulating CXCL12/CXCR4 signaling. Data presented in this
thesis indicates that CXCR2 also mediates G-CSF induced neutrophil release and
possibly neutrophil transmigration and subsequent dampening of IL-23 production.
Modified with permission from Christopher and Link (13).
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Figure 1-4. Mechanisms of neutrophil mobilization by G-CSF. (A) Irradiated wildtype mice were reconstituted with G-CSFR-deficient hematopoietic cells (left panel) or
vice versa (right panel). In the stromal model, G-CSF signaling in non-hematopoietic
cells is sufficient for neutrophil mobilization, while in the right panel G-CSF signaling in
hematopoietic cells is required for neutrophil release into the blood. (B) Next, chimeric
mice were generated with a mixture of wild-type and G-CSFR-deficient hematopoietic
cells. On the left, cell-intrinsic G-CSF signals induce neutrophil release, while the trans
model predicts that G-CSF regulates secondary signals that mobilize neutrophils
independently of G-CSF signaling. Experimental data are consistent with the right
panels. Shaded cells, G-CSFR-deficient. Figure modified with permission from a review
by Link (225).
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Figure 1-5. Multi-step model of G-CSF-induced neutrophil mobilization. CXCL12
signaling through CXCR4 normally retains neutrophils in the bone marrow, thus
inhibiting their mobilization. G-CSF leads to neutrophil mobilization by inhibiting
CXCL12/CXCR4 signaling through direct inhibition of CXCR4 expression and indirect
suppression of CXCL12 production by osteoblasts. G-CSF signaling in monocytes
decreases osteoblast number by yet to be determined pathways. Given their key
anatomic position in the physical process of neutrophil mobilization, endothelial cells are
likely to play a role that is currently undefined.

61

Figure 1-6. Signal transduction pathways and regulation of CXCR4. CXCL12
binding to CXCR4 leads to the activation of multiple G protein-dependent signaling
pathways, resulting in diverse biological outcomes such as migration, adhesion, and
transcriptional activation. Pathways activated and outcomes elicited may differ between
CXCR4+ cell types. Two potential G protein-independent pathways have been
described. Tyrosine phosphorylation of CXCR4 results in the recruitment and activation
of the JAK/STAT pathway, while p38 and ERK activation has been shown to be partially
dependent on arrestin-3 (β-arrestin-2). Following activation, GRK phosphorylation
results in the recruitment of arrestin 2/3 (β-arrestin 1/2) and subsequent internalization.
CXCR4 is also ubiquitinated by AIP4 at the plasma membrane, which results in its
sorting to and degradation in lysosomes. However, a portion of the internalized receptor
may also recycle back to the plasma memebrane. Reprinted from a review by Busillo
and Benovic (144) with permission from Elsevier.
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Chapter 2

CXCR4 is a key regulator of neutrophil release from the bone
marrow under basal and stress granulopoiesis conditions

The research in this chapter was originally published in Blood.

Eash KJ, Means JM, White DW, and Link DC. CXCR4 is a key regulator of neutrophil
release from the bone marrow under basal and stress granulopoiesis conditions. Blood.
2009; 113(19): 4711-4719. © the American Society of Hematology.
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2.1

Abstract

The number of neutrophils in the blood is tightly regulated to ensure adequate protection
against microbial pathogens while minimizing damage to host tissue. Neutrophil
homeostasis in the blood is achieved through a balance of neutrophil production, release
from the bone marrow, and clearance from the circulation. Accumulating evidence
suggests that signaling by CXCL12, through its major receptor CXCR4, plays a key role
in maintaining neutrophil homeostasis. Herein, we generated mice with a myeloid
lineage-restricted deletion of CXCR4 to define the mechanisms by which CXCR4 signals
regulate this process. We show that CXCR4 negatively regulates neutrophil release from
the bone marrow in a cell autonomous fashion. However, CXCR4 is dispensable for
neutrophil clearance from the circulation. Neutrophil mobilization responses to
granulocyte colony stimulating factor (G-CSF), CXCL2, or Listeria monocytogenes
infection are absent or impaired, suggesting that disruption of CXCR4 signaling may be a
common step mediating neutrophil release. Collectively, these data suggest that CXCR4
signaling maintains neutrophil homeostasis in the blood under both basal and stress
granulopoiesis conditions primarily by regulating neutrophil release from the bone
marrow.
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2.2

Introduction

Neutrophils play an essential role in the innate immune response, as they are required to
effectively protect the host against a variety of bacterial and fungal pathogens. Under
basal conditions, the great majority of neutrophils reside in the bone marrow. In response
to infection or other stresses, this pool of neutrophils can be mobilized into the blood,
providing the host with a mechanism to rapidly increase neutrophil delivery to sites of
infection. It is essential that neutrophil number in the blood be tightly regulated.
Persistent neutropenia is associated with profound immunodeficiency, while excessive
neutrophil infiltration and activation contributes to tissue damage in certain inflammatory
disorders, such as rheumatoid arthritis. Neutrophil homeostasis is maintained through a
balance of neutrophil production, release from the bone marrow, and clearance from the
circulation (1). Contributing to the complexity of this process, neutrophils have the
shortest survival of any circulating cell, with reported half-lives of 8-16 hours under basal
conditions (2-7). Despite its importance, the mechanisms regulating neutrophil number
in the blood are incompletely understood.
Accumulating evidence suggests that the chemokine CXCL12 (stromal derived
factor-1, SDF-1), through interaction with its major receptor CXCR4, plays a key role in
controlling neutrophil homeostasis (8). Mice deficient for CXCL12 or CXCR4 die
perinatally, but the fetal circulation is characterized by elevated numbers of neutrophils
and a failure to establish bone marrow myelopoiesis (9-12). In CXCR4-/- fetal liver
chimeras, mature neutrophils and granulocytic precursors are increased in the blood,
while the number of mature neutrophils in the bone marrow is reduced (13, 14). Humans

65

and mice treated with AMD3100, a selective antagonist of CXCR4, or CXCR4 blocking
antibodies display a rapid mobilization of neutrophils into the blood (15-17). Truncation
mutations of CXCR4 that cause increased receptor signaling are responsible for most
cases of WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) syndrome,
which is characterized by abnormal retention of neutrophils in the bone marrow (18-20).
Importantly, CXCR4 is expressed by neutrophils as well as most other hematopoietic
cells, and CXCL12 is constitutively expressed at high levels in the bone marrow stroma
(21, 22). Together, these data support a model in which CXCL12 signaling through
CXCR4 provides a key retention signal for neutrophils in the bone marrow and therefore
negatively regulates their release.
As noted previously, peripheral blood neutrophil counts can increase rapidly in
response to infection or other stress. A wide variety of infectious agents, bacterial
products, cytokines, and chemokines are thought to contribute to this “emergency” or
“stress” granulopoiesis response (23, 24). The downstream signals that regulate this
response are relatively undefined, but recent evidence suggests that CXCR4 may play a
role. Treatment with granulocyte colony-stimulating factor (G-CSF), a key cytokine in
the stress granulopoiesis response, results in a decrease in CXCL12 expression in the
bone marrow and the downregulation of CXCR4 expression on neutrophils (25-28).
These observations suggest the hypothesis that disruption of CXCR4 signaling is a key
step mediating neutrophil release by G-CSF. Whether disruption of CXCL12/CXCR4
signaling is a common mechanism by which other mobilizing agents increase neutrophil
counts in the blood is unknown.
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Neutrophil homeostasis in the blood is determined, in part, by the rate of
clearance from the circulation. Neutrophils are cleared primarily in the liver, spleen, or
bone marrow, where apoptotic or aged neutrophils are thought to be phagocytosed by
macrophages (17, 29, 30). Recent studies suggest that CXCR4 may play a role the
clearance of aged, senescent neutrophils, particularly at bone marrow sites. CXCR4
expression increases on neutrophils as they age, and blocking antibodies to CXCR4
impede neutrophil homing to the bone marrow (17, 31). Thus, CXCR4 may have a dual
role in regulating neutrophil homeostasis by acting as a signal clearing senescent
neutrophils from the blood in addition to regulating neutrophil release.
The broad expression of CXCR4 on hematopoietic cells complicates the analysis
of this gene during granulopoiesis. For example, CXCR4-/- fetal liver chimeras display
defects in multiple hematopoietic lineages, including hematopoietic stem cells (13, 14,
32). Therefore, in the present study we use transgenic mice carrying a myeloid specific
deletion of CXCR4 to further define the role of CXCR4 in basal and stress
granulopoiesis. Using this system, we show that CXCR4 is dispensable for neutrophil
clearance from the blood. In contrast, CXCR4 is required for neutrophil mobilization
from the bone marrow in response to G-CSF, CXCL2 (growth regulated gene β, GROβ),
or Listeria monocytogenes infection. These results suggest that CXCR4 signaling is an
essential regulator of neutrophil homeostasis under both basal and stress granulopoiesis
conditions.

67

2.3

Methods

2.3.1

Mice. The LysMCre and CXCR4+/- mice (12, 33) were obtained from The Jackson

Laboratory (Bar Harbor, ME) and conditional CXCR4 (CXCR4flox/flox) (34) mice were
obtained from Dr. Dan R. Littman (New York University). All mice were inbred onto a
C57BL/6 background at least 10 generations. Mice were genotyped by PCR as described
(12, 33, 34). Congenic wild-type C57BL/6 mice (B6.SJL-Ptprc* Pep3b BoyJ, The
Jackson Laboratory) that have the Ly 5.1 gene were used to facilitate analysis of chimeric
mice. Sex- and age-matched mice between 6 and 16 weeks of age were used in
accordance with the guidelines of the Washington University Animal Studies Committee.

2.3.2

CXCR4 genotyping. Peripheral blood neutrophils (Gr-1brightSSChi) from

CXCR4flox/- or LysMCre/+ CXCR4flox/- mice were isolated using a MoFlo high-speed cell
sorter (Dako, Carpinteria, CA). Genomic DNA was prepared using the ArchivePure
DNA kit (5Prime, Gaithersburg, MD). The presence of either a floxed or deleted CXCR4
allele was revealed by PCR amplification using the listed primers. Floxed: 5'CCACCCAGGACAGTGTGACTC TAA-3' and 5'GATGGGATTTCTGTATGAGGATTAGC-3' Deleted: 5'-TCTAACGTCCCA
GATCCACC-3' and 5'-AACCAAACAAACCATCACACAG-3'.

2.3.3

Blood, bone marrow, or spleen analysis. Blood, bone marrow, and spleen cells

were harvested from mice using standard techniques, and the number of nucleated cells in
these tissues quantified using a Hemavet automated cell counter (CDC Technologies,
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Oxford, CT). In some cases, manual leukocyte differentials were performed on Wrightstained blood smears (minimum 100 cells) or bone marrow cytospins (minimum 300
cells). As reported previously,(26) the percentage of total body neutrophils in the blood
was estimated using the neutrophil distribution index (NDI), which is calculated by
dividing the number of neutrophils in the blood by the number in the blood and bone
marrow. Blood and bone marrow neutrophils were calculated assuming a blood volume
of 1.8 ml and a whole femur equivalent to 6% of the total bone marrow (35).

2.3.4

Flow cytometry. Cells from bone marrow, blood, or spleen were depleted of red

cells by hypotonic lysis, resuspended in phosphate-buffered saline (PBS) supplemented
with 0.2% bovine serum albumin (BSA) and 0.1% sodium azide (FACS buffer),
incubated for 10 minutes with anti-CD16/32 (Fc-block, BD Biosciences, San Diego, CA)
and stained for 20-30 minutes at 4°C with one or more of the following antibodies as
described in the text: allophycocyanin (APC)-conjugated anti-Ly6G (Gr-1,
Invitrogen/Caltag, Carlsbad, CA), biotinylated anti-CXCR4 (eBioscience, San Diego,
CA), biotinylated anti-CD115 (GM-CSFR, eBioscience), PerCP-Cy5.5-conjugated antiCD3e (BD Biosciences), PerCP-Cy5.5-conjugated anti-Ly5.1 (CD45.1, BD Biosciences),
fluorescein (FITC)-conjugated anti-Ly5.2 (CD45.2, eBioscience), Alexa488-conjugated
anti-F4/80 (Invitrogen), and APC-Alexa750-conjugated anti-CD45R (B220, Invitrogen).
Biotinylated antibodies were detected with phycoerythrin (PE)-conjugated streptavidin
(eBioscience). Isotype-matched antibodies and unstained cells were used as negative
controls. Mature neutrophils were gated as Gr-1hiSSChi cells, and in some experiments
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F4/80 or CD115 was used to further exclude blood monocytes. Data was collected on a
FACScan 5-color, 2-laser flow cytometer (BD Biosciences and Cytek Development,
Fremont, CA) using Cellquest software (BD Biosciences) and analyzed with the Flowjo
software package (Tree Star, Ashland, OR).

2.3.5

Colony-forming cell assay. Twenty µl of blood, 1 x 105 nucleated spleen cells, or

2 x 104 bone marrow cells were plated in 2.5 ml methylcellulose media supplemented
with a cocktail of recombinant cytokines (MethoCult 3434, Stemcell Technologies,
Vancouver, BC, Canada) or 10 ng/ml recombinant human G-CSF (M3231, Stemcell
Technologies). Cultures were plated in duplicate and placed in a humidified chamber
with 6% CO2 at 37°C. Colonies containing at least 50 cells were counted on days 7-10 of
culture.

2.3.6

Bone marrow transplantation. Wild type (Ly5.1) or LysMCre/+ CXCR4flox/-

(Ly5.2) bone marrow cells were harvested. A total of 2 million bone marrow cells were
mixed at a 1:1 ratio and injected retroorbitally into lethally irradiated wild type mice
(Ly5.1). Recipient mice were conditioned with 1,000 cGy from a 137Cesium source at a
rate of approximately 95 cGy/min prior to transplantation. Prophylactic antibiotics
(trimethoprim-sulfamethoxazole, Alpharma, East Bridgewater, NJ) were given during the
initial 2 weeks following transplantation. Mice were analyzed 8-10 weeks after
transplantation.
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2.3.7

BrdU labeling. Bromodeoxyuridine (BrdU, 10 mg/ml solution in 1x Dulbecco’s

PBS, Sigma, St. Louis, MO) was given by a single intraperitoneal injection at a dose of 12 mg/mouse. The percentage of BrdU+/Gr-1+ cells was determined by staining with APCconjugated Gr-1 antibody followed by fixation, permeablization, and intracellular
staining with a FITC-conjugated anti-BrdU antibody using reagents from the BrdU Flow
kit (BD Biosciences). The half-life (t1/2) of neutrophils in the blood was calculated using
the formula N = N0e-λt where N0 = the peak number of labeled cells, N = the number of
cells at time t and λ = the decay constant.

2.3.8

Adoptive transfer experiments. Bone marrow cells were harvested, red blood

cells removed by hypotonic lysis at room temperature for 2 minutes, and 8-10 x 106 cells
injected intravenously into unconditioned wild type (Ly5.1) recipients. Bone marrow
cells were harvested 1.5 to 2.5 hours after infusion, and donor neutrophils were identified
based on Gr-1 and Ly5.2 expression. The absolute number of donor neutrophils in the
bone marrow was calculated assuming a whole femur equivalent to 6% of the total bone
marrow (35). This number was divided by the total number of donor neutrophils that
were infused to yield the percentage of donor neutrophils that had homed to the bone
marrow.

2.3.9

Neutrophil mobilization. G-CSF: recombinant human G-CSF, a generous gift

from Amgen (Thousand Oaks, CA), was diluted in PBS with 0.1% low endotoxin BSA
(Sigma) and administered by twice daily subcutaneous injection at a dose of 125
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μg/kg/day for 5 days. Mice were analyzed 3-4 hours after the final injection on day 5.
Some cohorts of mice were given a single subcutaneous injection of G-CSF (125 μg/kg),
and peripheral blood was analyzed at the indicated times.
GROβ: human GROβ, a generous gift from Genzyme (Cambridge, MA), was
reconstituted in sterile PBS and administered as a single subcutaneous injection at a dose
of 100 μg/kg. Peripheral blood was analyzed at the indicated times.

2.3.10 Listeria monocytogenes infection. Mice were infected intraperitoneally with a
dose of 5 x 105 colony forming units (c.f.u) of L. monocytogenes strain EGD. Peritoneal
cells were obtained by lavage with 10 ml of cold PBS, nucleated cells counted, and
manual leukocyte differential counts (200 cells) performed on Wright-stained cytospins.
At 72 hours, L. monocytogenes was quantified by homogenizing the spleens and livers in
10 ml PBS with 0.05% Triton X-100 and plating serial dilutions on LB-agar.

2.3.11 Statistical analysis. Statistical significance was assessed using a two-tailed
Student t test assuming equal variance for comparison of two groups, one-way ANOVA
with Bonferroni post-testing for experiments with more than two groups, or, for timecourse experiments, a 2-way ANOVA with Bonferroni post-testing at individual time
points. All data are presented as the mean ± SEM.
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2.4

Results

2.4.1

CXCR4 is selectively deleted in myeloid cells of LysMCre/+ CXCR4flox/-

(MKO) mice
Mice expressing Cre-recombinase under the control of the myeloid lysozyme M promoter
(LysMCre) were crossed with CXCR4+/- and CXCR4flox/flox mice to generate myeloidrestricted knockout (MKO) mice with the genotype LysMCre/+ CXCR4flox/-. Efficient
deletion of CXCR4 in mature neutrophils (Gr-1brightSSChi) of MKO mice in both the
blood and bone marrow was observed by flow cytometry. Whereas CXCR4 expression
was easily detectable in wild type neutrophils in the blood, no expression was detected in
MKO neutrophils (Figure 2-1 A & B). CXCR4+/- mice had intermediate levels of
CXCR4 expression on their neutrophils. There was some residual expression of CXCR4
in MKO bone marrow neutrophils, possibly representing less mature myeloid cells that
had not yet undergone Cre-mediated excision of CXCR4. As expected, expression of
CXCR4 was normal to slightly reduced in B lymphocytes and T lymphocytes from MKO
mice compared to wild type mice (Figure 2-1A and data not shown). PCR analysis of
genomic DNA isolated from MKO blood neutrophils confirmed complete Cre-mediated
excision of the coding region of exon 2 of the CXCR4 gene (Figure 2-1C). These data
show that CXCR4 is efficiently and specifically deleted in myeloid cells in MKO mice.
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2.4.2

Loss of CXCR4 results in the redistribution of neutrophils from the bone

marrow to blood
To assess the effect of the loss of CXCR4 on basal granulopoiesis, MKO or control mice
housed in standard pathogen free conditions were analyzed. We initially analyzed 4
separate control groups: wild type mice, CXCR4flox/+ mice, LysMCre/+ CXCR4+/+ mice, and
CXCR4+/- mice. The wild type, CXCR4flox/+, and LysMCre/+ CXCR4+/+mice had similar
phenotypes for all assays and were subsequently pooled as control mice (Figure 2-2 and
data not shown). MKO mice displayed a marked isolated neutrophilia in the peripheral
blood (Figure 2-2A). The number of Gr-1brightSSChi cells (neutrophils) in the blood was
1.7 ± 0.2 x 106/ml in control mice versus 8.5 ± 0.4 x 106/ml in MKO mice (p < 0.0001).
This increase in circulating neutrophils was confirmed by manual inspection and
differential counts of blood smears [absolute neutrophil count: 1.6 ± 0.4 x 106/ml (control
mice) versus 5.3 ± 0.7 x 106/ml (MKO mice); p < 0.001]. Interestingly, no increase in
immature myeloid cells in the blood was observed (data not shown). MKO mice
displayed normal numbers of circulating B lymphocytes and T lymphocytes (data not
shown). They also had normal numbers of circulating and splenic hematopoietic
progenitor cells as measured by colony forming assays (data not shown).
In the bone marrow of MKO mice, the number of Gr-1brightSSChi cells was
reduced to 71.8 ± 2.9% of control mice (Figure 2-2B). Although the Gr-1brightSSChi cell
population reliably measures mature neutrophils in the blood, this population is more
heterogeneous in the bone marrow with approximately 20% immature myeloid cells (36).
Thus, to confirm these findings, we also performed manual leukocyte differentials of
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bone marrow cells (Figure 2-3). Consistent with the flow cytometry data, a trend to
decreased band and segmented neutrophils in the bone marrow of MKO mice was
observed (control, 6.3 ± 0.9 x 106/femur versus MKO, 4.2 ± 1.0 x 106/femur; p = 0.14).
Of note, the frequency of granulocytic precursors and number and cytokine
responsiveness of myeloid progenitors was comparable in MKO and control mice
(Figures 2-3 & 2-4), suggesting that neutrophil differentiation was normal.
Neutrophil trafficking from the bone marrow was estimated by determining the
percentage of neutrophils in the blood versus the total number of neutrophils in the bone
marrow and blood (26). Consistent with previous reports, in control mice, only 1.9 ±
0.2% of neutrophils are in the blood. Strikingly, in MKO mice, this percentage increased
to 11.9 ± 1.2% (Figure 2-2C; p < 0.0001). There also was a significant increase in
splenic neutrophils in MKO mice [number of neutrophils per spleen: 4.3 ± 1.3 x 106
(control) versus 13.3 ± 1.8 x 106 (MKO); p < 0.01]. Collectively, these data suggest that
the loss of CXCR4 results in the redistribution of neutrophils from the bone marrow to
the blood and spleen.

2.4.3

Loss of CXCR4 results in premature release of neutrophils from the bone

marrow but normal clearance from the blood
An increase in circulating neutrophil number could be caused by increased production of
neutrophils in the bone marrow, increased release into the blood, decreased clearance
from the blood, or some combination thereof. To investigate differences in kinetics of
neutrophil release into the blood and the potential difference in neutrophil survival,
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control or MKO mice were given a single injection of bromodeoxyuridine (BrdU) to
label newly synthesized neutrophils. The fate of blood neutrophils pulse-labeled with
BrdU in vivo was determined by flow cytometry for Gr-1+BrdU+ cells (Figure 2-5A). In
the bone marrow, a similar percentage of myeloid cells were labeled with BrdU,
suggesting that loss of CXCR4 does not affect granulocytic cell proliferation (data not
shown). Consistent with a role for CXCR4 in regulating neutrophil release, the transit
time for labeled neutrophils to appear in the circulation was significantly reduced in
MKO mice. In control mice, the peak number of labeled neutrophils in the blood
occurred 72 hours after BrdU administration, while in the majority of MKO mice, the
peak was at 46 hours (Figure 2-5B). However, there was no significant difference in the
disappearance of labeled cells from the blood. Consistent with previous studies in mice
and humans, the calculated half-life of control neutrophils was 13.7 ± 2.3 hours. A
similar calculated half-life was observed for MKO neutrophils (10.0 ± 1.0 hours, Figure
2-5C). Taken together, these data show that neutrophils lacking CXCR4 have accelerated
release from the bone marrow but normal clearance from the blood.

2.4.4

CXCR4 directs homing of neutrophils to the bone marrow

Previous studies suggested that aged neutrophil preferentially home to, and are cleared in,
the bone marrow in a CXCR4-dependent fashion (17, 31). To test this possibility, we
measured the trafficking of neutrophils to the bone marrow after adoptive transfer of
control or MKO neutrophils into wild type recipient mice. Donor neutrophils from
control mice were clearly detectable in recipient bone marrow 1.5-2.5 hours after
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transfer. However, homing of MKO neutrophils to the bone marrow was significantly
reduced, although not eliminated completely (Figure 2-6). These data confirm that
CXCR4 contributes to neutrophil homing to the bone marrow. However, given the
normal circulating half-life of endogenous MKO neutrophils, it appears that the bone
marrow is not an essential site of neutrophil clearance.

2.4.5

CXCR4 acts in a cell autonomous fashion to retain neutrophils in the bone

marrow
Recent studies suggest that loss of adhesion molecules on neutrophils may result in
neutrophilia in a non-cell autonomous fashion through disruption of a homeostatic
feedback loop (37, 38). To determine whether CXCR4 acts in a cell autonomous fashion
to regulate neutrophil release, mixed bone marrow chimeras were generated in which
hematopoiesis was reconstituted with a 1:1 ratio of wild type to MKO cells. The mixed
chimeras displayed chronic neutrophilia (absolute neutrophil count of 5.8 ± 0.4 x
106/mL). Whereas the percentage of wild type and MKO neutrophils in the bone marrow
was similar, the great majority of neutrophils in the blood were derived from MKO cells
(Figure 2-7A). Accordingly, the calculated neutrophil distribution index for MKO cells
(23.9 ± 2.5%) was much higher than that for wild type neutrophils (4.3 ± 0.6%; p <
0.0001; Figure 2-7B). As a control, we also assessed the distribution of B lymphocytes in
the mixed chimeras. Though a modest increase in MKO-derived B lymphocytes was
observed, the ratio of MKO to wild type cells in the bone marrow and blood was similar
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(Figure 2-7C). These data show that CXCR4 negatively regulates neutrophil release in a
cell autonomous fashion.

2.4.6

Neutrophil mobilization by G-CSF or GROβ is impaired in the absence of

CXCR4
A key feature of the innate immune response is the capacity to rapidly increase neutrophil
number in the blood in response to infection or other stresses. Certain cytokines,
chemokines, and bacterial products are thought to mediate the stress granulopoiesis
response. To examine the contribution of CXCR4 signaling in stress granulopoiesis, we
first characterized the neutrophil response to G-CSF, the prototypical mobilizing
cytokine. Following a single injection of G-CSF, neutrophil number in the blood of
control mice increased 3.9 ± 0.7 fold (Figure 2-8A), with peak levels occurring after 6
hours before returning to near-baseline levels at 24 hours. As reported previously (25),
this was associated with a marked decrease in surface CXCR4 expression on blood
neutrophils (Figure 2-8B). In contrast, no change in neutrophil counts in the blood was
observed after G-CSF treatment of MKO mice (Figure 8A). Next, we studied
granulopoiesis after 5 days of G-CSF administration. In control mice, an 11.8 ± 1.6 fold
increase in circulating neutrophils was observed (Figure 2-8C). This increase was
secondary to both increased production (as evidenced by a modest increase in bone
marrow neutrophils) and increased neutrophil release (as evidenced by an increase in the
NDI). Of note, previous studies showed that G-CSF does not alter the kinetics of
neutrophil clearance from the blood (2, 3, 26). In MKO mice, a similar increase in bone
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marrow neutrophils after G-CSF treatment was observed, suggesting that G-CSF induced
increases in neutrophil production were intact. In contrast, though a modest increase in
circulating neutrophils was observed in MKO mice after G-CSF treatment, this appears to
be mainly secondary to increased production, rather than release, as no increase in the
NDI was seen.
We also examined neutrophil release after treatment with GROβ, a wellcharacterized mobilizing chemokine. In control mice, GROβ treatment induced a 7.4 ±
2.1 fold increase in circulating neutrophils that peaked 30 minutes after injection and
nearly returned to baseline after two hours (Figure 2-8D). In contrast, no significant
increase in circulating neutrophils was observed in MKO mice. Surprisingly, CXCR4
expression on neutrophils isolated from control mice treated with GROβ was
significantly reduced at the time of peak mobilization compared to pre-treatment levels
(Figure 2-8E). These data suggest that G-CSF and GROβ induced neutrophil release
from the bone marrow are dependent on CXCR4 signals.

2.4.7

Neutrophil mobilization in response to Listeria monocytogenes infection is

impaired in the absence of CXCR4 but homing of neutrophils to the peritoneum and
bacterial clearance is normal
To further define the requirement for CXCR4 in emergency granulopoiesis, control and
MKO mice were infected intraperitoneally with Listeria monocytogenes. Infection with
L. monocytogenes is an established model of emergency granulopoiesis, and neutrophils
are known to play a key role in the clearance of this infection (39). Clearance of bacteria
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was similar in MKO and wild type mice; no difference in survival or spleen and liver
bacterial load was observed after L. Monocytogenes challenge (Figure 2-9 A & B). In
control mice, a 3.4 ± 0.6 fold increase in circulating neutrophils was observed 24 hours
after bacterial challenge that remained elevated for the duration of the assay. In contrast,
MKO mice failed to increase their circulating neutrophils in response to infection with
this pathogen (Figure 2-9C). However, neutrophils in MKO mice were able to emigrate
into the peritoneal space in similar numbers compared to control mice (Figure 2-9D).
These data show that CXCR4, while required for maximal neutrophil mobilization into
the blood after L. monocytogenes infection, is dispensable for neutrophil emigration to
the peritoneum.
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2.5

Discussion

There is accumulating evidence suggesting that CXCR4 is a key regulator of neutrophil
homeostasis. Perhaps most convincing is the identification of truncation mutations of
CXCR4 in most cases of WHIM syndrome. Patients with WHIM syndrome display
neutropenia despite normal to increased numbers of neutrophils in the bone marrow. The
CXCR4 truncation mutations confer enhanced responsiveness to CXCL12, suggesting a
model in which increased CXCR4 signaling in WHIM neutrophils results in their
abnormal retention in the bone marrow (18, 19, 40, 41). Consistent with this model,
treatment of humans or mice with AMD3100, a specific CXCR4 antagonist, results in the
rapid mobilization of neutrophils into the blood (15, 16). However, direct testing of the
contribution of CXCR4 to neutrophil homeostasis has been limited by the embryonic
lethality of CXCR4 deficient mice and the severe engraftment defect of CXCR4-/hematopoietic stem cells (10, 11, 13, 32). In the present study, we characterized
granulopoiesis and neutrophil trafficking in transgenic mice carrying a myeloid-specific
deletion of CXCR4. The marked neutrophilia present in these mice confirm a key role
for CXCR4 signaling in the regulation of neutrophil homeostasis.
Neutrophil homeostasis in the blood is maintained by balancing neutrophil
production, release from the bone marrow, and clearance. There is evidence implicating
CXCR4 in the regulation of all three of these processes. In WHIM syndrome, there are
reports of dysmorphic neutrophils and increased neutrophil apoptosis, suggesting
defective granulopoiesis (42, 43). Moreover, in CXCR4-/- fetal liver chimeras, there is a
decrease in myeloid progenitors and precursors (13). Our study was not designed to
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assess the contribution of CXCR4 to granulopoiesis, since CXCR4 expression in MKO
mice was maintained until the final stages of myeloid development. Not surprisingly,
granulopoiesis, as measured by leukocyte differentials, BrdU incorporation in myeloid
precursors, and number and cytokine responsiveness of myeloid progenitors, was normal
in MKO mice. Despite normal granulopoiesis, marked neutrophilia and increased splenic
neutrophils were observed in MKO mice, suggesting an alteration in neutrophil release or
clearance.
As noted previously, the rapid mobilization of neutrophils into the blood by
AMD3100 suggests a role for CXCR4 in regulating neutrophil release. Indeed, the
striking redistribution of neutrophils from the bone marrow to blood in MKO mice
suggests enhanced neutrophil release. Consistent with this conclusion, BrdU labeled
neutrophils appeared in the blood more rapidly in MKO versus control mice. A recent
report suggested that CXCR4 may contribute to neutrophil clearance from the blood by
directing senescent neutrophils to the bone marrow (31). Consistent with this finding, we
observed decreased homing of CXCR4 deficient neutrophils to the bone marrow after
adoptive transfer. On the other hand, the half-life of CXCR4 deficient neutrophils in the
blood was comparable to wild type neutrophils, suggesting that CXCR4 is not a major
regulator of neutrophil clearance from the blood and that the bone marrow represents a
non-essential site of neutrophil removal. Collectively, these data suggest that CXCR4
maintains neutrophil homeostasis primarily by regulating neutrophil release from the
bone marrow.
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Neutrophil homeostasis can be regulated in both a cell autonomous and non-cell
autonomous fashion. In a series of elegant studies, Stark and colleagues showed that β2integrin deficient neutrophils induced neutrophilia in a non-cell autonomous fashion
through the suppression of a negative feedback loop that senses the number of
neutrophils that have emigrated into the tissue (37, 38). They showed that the presence
of even a small number of wild type neutrophils activated the feedback loop and restored
normal neutrophil number in the blood. In contrast, we observed persistent neutrophilia
and preferential release of CXCR4 deficient neutrophils in mixed bone marrow chimeras
reconstituted with both wild type and MKO bone marrow cells. These data show that
CXCR4 acts in a cell autonomous fashion to regulate neutrophil release from the bone
marrow.
G-CSF, the prototypical neutrophil mobilizing cytokine, is key regulator of both
basal and stress granulopoiesis (44). Previous studies have shown that treatment with GCSF results in a decrease in CXCL12 expression in the bone marrow (26-28). Moreover,
G-CSF treatment leads to decreased surface expression of CXCR4 on neutrophils, a
finding confirmed in the present study (25). These data suggest the hypothesis that
disruption of CXCR4 signaling may contribute to G-CSF induced neutrophil
mobilization. However, G-CSF treatment also induces other changes in the bone marrow
microenvironment, such as the release of proteases (45), that might contribute to
neutrophil mobilization. Thus, the relative importance of CXCR4 signaling in mediating
neutrophil mobilization by G-CSF is unclear. In the present study, we show that G-CSF,
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though stimulating neutrophil production, did not stimulate neutrophil release from the
bone marrow in the absence of CXCR4 signals.
Of note, despite the near normal number of morphologically mature neutrophils in
the bone marrow, it is possible that the mobilizable pool of neutrophils in MKO mice is
exhausted. Arguing against this possibility, blood neutrophil counts in MKO mice
doubled after the administration of a solution of propylene glycol (data not shown).
Collectively, these data suggest that disruption of CXCL12/CXCR4 signaling is the
dominant pathway by which G-CSF induces neutrophil mobilization.
Besides G-CSF, there are a number of neutrophil mobilizing agents that are
thought to contribute to the stress granulopoiesis response. Most notable among these
agents are chemokines. The rapidity of neutrophil mobilization by chemokines (minutes
to hours) compared with G-CSF (hours to days) suggests distinct mechanisms of
mobilization. Consistent with this idea, the CXCR2-chemokine KC (CXCL1) can
synergize with G-CSF or AMD3100 to induce neutrophil mobilization (17, 31, 46).
Surprisingly, herein we show that GRO -induced neutrophil mobilization is abrogated in
MKO mice. This result suggests two possibilities: 1). The GRO -mobilizable pool of
neutrophils is depleted in MKO mice. 2). GRO -induced mobilization is dependent on
CXCR4 signaling in neutrophils. In support of the latter possibility, several recent
reports showed that treatment of wild type neutrophils or monocytes with CXCR2 ligands
resulted in impaired CXCR4 signaling, presumably through heterologous desensitization
(17, 47). In addition, we observed a significant decrease in cell-surface CXCR4
expression on neutrophils after GRO treatment. Together, these data suggest that
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disruption of CXCL12/CXCR4 signaling is a common mechanism by which chemokines
and cytokines induce neutrophil release.
The stress granulopoiesis response to infection requires the coordinated
expression of many different cytokines and chemokines. In this study, we utilized a
model of L. monocytogenes infection to further explore the contribution of CXCR4
signals in the stress granulopoiesis response. Interestingly, the neutrophil mobilization
response in MKO mice following L. monocytogenes infection was abrogated, suggesting
that modulation of CXCR4 signaling may be a common mechanism of neutrophil release.
In summary, our data provide new evidence that CXCR4 is a key regulator of
neutrophil homeostasis under basal and stress conditions. CXCR4 signals act primarily
to regulate neutrophil trafficking from the bone marrow, and disruption of CXCR4
signals may represent a common mechanism by which cytokines and chemokines induce
neutrophil release from the bone marrow. These data suggest that pharmacologic agents
that modulate CXCR4 signaling may be effective for controlling neutrophil responses in
infectious and inflammatory diseases.
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2.8

Figures and figure legends

Figure 2-1. CXCR4 is efficiently deleted in neutrophils from LysM Cre/+ CXCR4flox/(MKO) mice. (A) Representative histograms showing cell surface CXCR4 expression in
the mature neutrophil (Gr-1brightSSChi) population from bone marrow or peripheral blood
or the peripheral blood B lymphocyte (B-220+) population in wild type (WT) or MKO mice.
The isotype control (ISO) is shown in gray. (B) Cell surface CXCR4 expression in the
mature neutrophil population in the bone marrow or peripheral blood. Data represent the
mean ± SEM. #p < 0.05 compared to wild type mice. *p < 0.05 compared to CXCR4+/mice. (C) Genomic DNA was isolated from MKO or control (CXCR4flox/- without LysMCre)
blood neutrophils and the CXCR4 gene amplified using primers that specifically detected
the deleted (CXCR4∆), floxed (CXCR4flox), or null (CXCR4-) CXCR4 alleles.
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Figure 2-2. Basal granulopoiesis in MKO mice is characterized by a shift of
neutrophils from the bone marrow to the blood. (A & B) The number of mature
neutrophils (Gr-1brightSSChi) in the blood and bone marrow was quantified by flow
cytometry in mice of the indicated genotype. (C) The neutrophil distribution index (NDI)
was calculated to estimate the percentage of total body neutrophils in the blood, using
the following formula: NDI = blood neutrophils / (blood + bone marrow neutrophils). Data
represent the mean ± SEM. #p < 0.05 compared to all other groups.
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B
Blasts and
Band and
ProSegmented
Metamyelocytes Myelocytes myelocytes Neutrophils
CTL
MKO

Erythroid
Cells

Lymphoid
Cells

Other

8.0 ± 1.9% 14.9 ± 1.2% 15.8 ± 3.0% 18.4 ± 2.8% 29.3 ± 4.0% 12.1 ± 1.3% 1.6 ± 0.1%
6.7 ± 0.2% 15.8 ± 1.5% 15.5 ± 1.4% 10.5 ± 2.5% 37.3 ± 2.0% 12.6 ± 0.7% 1.7 ± 0.5%

Figure 2-3. Morphologically mature neutrophils are present in the bone marrow of
MKO mice. (A) Representative micrographs of bone marrow cytospins from two
different MKO mice or a wild type (WT) mouse demonstrating the presence of band and
segmented neutrophils. Original magnification x1000. Images were acquired using an
E plan 100x/1.25 NA oil immersion objective, Microphot SA microscope, Digital Sight
DS-Fi1 camera, and NIS-Elements F2.30 software, all from Nikon (Melville, NY). (B)
Manual leukocyte differential counts were performed on control (CTL) or MKO mice.
Data represent the mean ± SEM (n = 3 mice per group).
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Figure 2-4. MKO mice have normal numbers of myeloid progenitors in the bone
marrow. Bone marrow cells from control (CTL) or MKO mice were plated in
methylcellulose medium in the presence of stem cell factor, IL-3, IL-6, and EPO (CFU-C)
or G-CSF (CFU-G) and colonies enumerated on day 7-10 of culture. Data represent the
mean ± SEM (n = 5 mice per group).

93

Figure 2-5. Blood neutrophil half-life in MKO mice is normal. BrdU (2 mg) was
administered to control (CTL) or MKO mice by a single intraperitoneal injection.
Peripheral blood was obtained at the indicated time points and the number of BrdU+ Gr1bright cells determined by flow cytometry. (A) Representative dot plots showing BrdU
staining in the Gr-1bright (mature neutrophil) population. The numbers shown indicate the
percentage of Gr-1bright cells that were BrdU+. (B) The absolute number of BrdU+ Gr1bright neutrophils in the blood is shown. (C) Neutrophil half-life (t1/2) in the blood was
calculated according to the formulas t1/2 = ln 2/λ and nt = n0e-λt where n0 is the number at
a given time, nt is the number t hours later, and λ is the decay constant. The data shown
represent the mean ± SEM of n = 10-11 mice in each group. *p < 0.05 compared to
control mice at the same time point. ns, not significant.
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Figure 2-6. MKO neutrophils have impaired homing to the bone marrow. Bone
marrow cells (8-10 x 106) from control (CTL) or MKO mice carrying the Ly 5.2 allele were
adoptively transferred to WT recipients carrying the Ly 5.1 allele, enabling detection of
infused neutrophils in the bone marrow by flow cytometry using an allele-specific CD
45.2 antibody. (A) Representative dot plots showing donor neutrophils as the
percentage of total bone marrow neutrophils 1.5-2.5 hours after infusion. (B) The
percentage of transferred control or MKO neutrophils present in the bone marrow of
recipient mice. Data represent the mean ± SEM of n = 8-12 recipients for each genotype
from 3 separate experiments. *p < 0.05 compared to control neutrophils.
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Figure 2-7. Trafficking of MKO neutrophils is altered in mixed chimeras. Whole
bone marrow from wild type (WT, Ly5.1) and MKO (Ly5.2) mice was mixed in a 1:1 ratio
and transplanted into lethally irradiated wild type (Ly5.1) recipients. After hematopoietic
reconstitution (8-10 weeks), the bone marrow and blood were analyzed by flow
cytometry. The numbers at the top of the columns indicate the fold increase over the
wild type cells. (A) Mature neutrophils (Gr-1bright CD115-). (B) Neutrophil distribution
index. (C) B lymphocytes (B220+). The data represent the mean ± SEM of n = 18
recipients from two separate transplants. *p < 0.05 compared to wild type cells.
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Figure 2-8. Neutrophil mobilization by G-CSF or GROβ is abrogated in MKO mice.
(A) Mice (n = 5 per group) were given a single subcutaneous injection of G-CSF (125
μg/kg) and the absolute neutrophil count measured at the indicated times. †p < 0.05
compared to time 0. (B) Representative histograms showing cell surface CXCR4
expression on blood neutrophils from control (CTL) or MKO mice at baseline and 65
minutes after a single dose of G-CSF (+G). (C) Mice (n = 8-11 per group) were treated
with G-CSF (125 μg/kg/day, twice daily injections) for 5 days, and neutrophils in the
bone marrow and blood were quantified. The calculated neutrophil distribution index is
shown in the far right panel. *p < 0.05 compared with control mice at the same time
point. #p < 0.05 compared to untreated mice of the same genotype. (D) Mice (n = 9-12
per group) were given a single subcutaneous injection of GROβ (100μg/kg), and the
absolute neutrophil count was determined at the indicated times. †p < 0.05 compared to
time 0. (E) CXCR4 cell surface expression on peripheral blood neutrophils from control
mice was determined by flow cytometry at baseline and at the time of peak mobilization,
30 minutes after GROβ administration. **p < 0.001. Data represent the mean ± SEM.
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Figure 2-9. MKO mice have impaired blood neutrophil mobilization but normal
neutrophil recruitment to the peritoneum in response to Listeria infection. Control
(CTL) or MKO mice were infected intraperitoneally with Listeria monocytogenes. (A)
Survival was assessed in mice (n = 12 per group) from two separate infections with 9.8
to 11.2 x 105 C.F.U. of bacteria. (B) The bacterial titer in the spleen and liver of control
and MKO mice (n = 8 per group) was determined 72 hours after infection with 2.1 to 7.2
x 105 C.F.U. of bacteria. (C) Blood neutrophil counts were assessed by flow cytometry at
the indicated times after infection with 2.1 to 9.8 x 105 C.F.U. of bacteria (n = 8-19 mice
per group depending on the time). (D) Shown is the number of neutrophils in the
peritoneum at the indicated times after infection with 2.1 to 7.2 x 105 C.F.U. of bacteria (n
= 5-8 mice per group depending on the time). Data represent the mean ± SEM. †p <
0.05 compared to time 0.
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Chapter 3

CXCR2 and CXCR4 antagonistically regulate neutrophil
trafficking from the bone marrow

This chapter has been published and is reproduced with permission from the American
Society for Clinical Investigation.

Eash KJ, Greenbaum AM, Gopalan PK, and Link DC. 2010. CXCR2 and CXCR4
antagonistically regulate neutrophil trafficking from the bone marrow. J. Clin. Invest.
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3.1

Abstract

Neutrophil homeostasis is maintained, in part, by the regulated release of neutrophils
from the bone marrow. Constitutive expression of the chemokine CXCL12 by bone
marrow stromal cells provides a key retention signal for neutrophils in the bone marrow
through activation of its receptor CXCR4. Herein, we show that the ELR+ chemokines
CXCL1 and CXCL2 are constitutively expressed by bone marrow endothelial cells and
osteoblasts, and CXCL2 expression is induced in endothelial cells during G-CSF-induced
neutrophil mobilization. Neutrophils lacking CXCR2, the receptor for CXCL1 and
CXCL2, are preferentially retained in the bone marrow, reproducing a myelokathexis
phenotype. Transient disruption of CXCR4 failed to mobilize CXCR2-/- neutrophils.
However, doubly deficient neutrophils (CXCR2-/- CXCR4-/-) displayed constitutive
mobilization, showing that CXCR4 plays a dominant role. Collectively, these data
suggest that CXCR2 signaling is a second chemokine axis that interacts antagonistically
with CXCR4 to regulate neutrophil release from the bone marrow.
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3.2

Introduction

Neutrophils are an essential component of the innate immune response and a major
contributor to inflammation. Accordingly, the number of neutrophils in the blood is
tightly regulated. Neutrophil homeostasis is maintained through a balance of neutrophil
production, release from the bone marrow, and clearance from the circulation (1). The
bone marrow is the primary site of neutrophil production, requiring that mature
neutrophils transmigrate through an endothelial cell barrier to enter the circulation (2-4).
Under basal conditions, less than 2% of the total body of mature neutrophils are in the
circulation (5). Thus, the bone marrow serves as a reservoir for neutrophils that can be
rapidly mobilized in response to infection or other stresses.
Major advances in our understanding of the mechansims regulating neutrophil
release from the bone marrow have come from the study of the human disease
myelokathexis (kathexis = retention) (6-8). Myelokathexis is characterized by
neutropenia despite normal to increased numbers of neutrophils in the bone marrow. It
can occur in isolation or as a component of WHIM (warts, hypogammaglobulinemia,
infections, myelokathexis) syndrome (WS) (9, 10). Genetic studies have shown that
heterozygous mutations of CXCR4 are the most common cause of WHIM syndrome (11).
CXCR4 encodes for a CXC chemokine receptor whose major ligand is CXCL12 (SDF-1)
(12). WHIM-associated mutations of CXCR4 result in the production of a carboxyterminal truncated receptor that displays impaired internalization and enhanced
signaling, suggesting that excessive CXCR4 signaling may result in abnormal neutrophil
retention in the bone marrow (13-16). Conversely, genetic deletion of CXCR4 in murine
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hematopoietic cells results in constitutitive mobilization of neutrophils into the blood (1722). Moreover, treatment of humans or mice with AMD3100, a small molecule
antagonist of CXCR4, causes rapid neutrophil mobilization (23, 24). Together with the
observation that CXCL12 is constituitively expressed at a high level by bone marrow
stromal cells (25), these data indicate that the CXCR4/CXCL12 axis provides a key
retention signal for neutrophils in the bone marrow.
Disruption of CXCR4 signaling is an important mechanism by which neutrophils
are mobilized into the circulation under stress conditions. Treatment with G-CSF, a
major mobilizing cytokine, is associated with decreased CXCL12 expression in the bone
marrow and decreased CXCR4 expression on neutrophils (5, 26-28). Yet, the
mechanisms by which attenuated CXCR4 signaling leads to migration of neutrophils
towards the bone marrow venous sinuses and subsequent entry into the circulation are
unclear. Based on their well-characterized role in other aspects of neutrophil biology
(29), we hypothesized that ELR+ CXC chemokines may direct neutrophil migration
towards the bone marrow vascular space, thereby opposing the CXCR4/CXCL12 axis.
There are 7 ELR+ CXC chemokines (CXCL1-3, 5-8) that signal through CXCR1 or
CXCR2 (12). These chemokines are potent neutrophil chemoattractants and activators
and induce neutrophil mobilization from the bone marrow when administered
exogenously (4, 30-33). Accordingly, CXCR2-/- mice have a profound defect in
neutrophil emigration to sites of inflammation (mice lack CXCR1) (34). With respect to
neutrophil homeostasis, CXCR2-/- mice housed under specific pathogen free (SPF)
conditions display neutrophilia with a myeloid expansion in the bone marrow and spleen.
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In contrast, under gnotobiotic conditions, the level of circulating neutrophils in CXCR2-/mice is normal, raising the possibility that subclinical infections are inducing a stress
granulopoiesis response (35-37).
In the present study, we generated mixed bone marrow chimeras reconstituted
with wild type and CXCR2-/- cells to study the cell-intrinsic role of CXCR2 in neutrophil
trafficking. We show that CXCR2-/- neutrophils are selectively retained in the bone
marrow, reproducing a myelokathexis phenotype. CXCR2 is required for neutrophil
mobilization in response to transient CXCR4 inhibition, although the increased release of
CXCR4-/- neutrophils is not altered in the absence of CXCR2 signals. CXCR2 ligands
CXCL1 (KC) and CXCL2 (MIP-2) are constitutively expressed in bone marrow
endothelium, and CXCL2 expression is induced during G-CSF-induced neutrophil
mobilization. These results suggest that CXCR2 signaling is a second chemokine axis
that controls neutrophil release from the bone marrow by opposing CXCR4 signals.
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3.3

Methods

3.3.1

Mice. Sex- and age-matched, congenic C57BL/6 CXCR2-/- (34, 38) (The Jackson

Laboratory, Bar Harbor, ME), LysMCre/+ CXCR4flox/- (22), pOBCol2.3-GFP (39), and
wild-type mice that have the Ly5.1 gene (B6.SJL-Ptprc* Pep3b BoyJ, Jackson Labs) were
maintained under SPF conditions according to methods approved by the Washington
University Animal Studies Committee. All transgenic strains had been backcrossed at
least 10 generations onto a C57BL/6 background.

3.3.2

Bone marow transplantation. Bone marrow cells from wild-type (Ly5.1+) mice

and either CXCR2-/-, CXCR4-MKO (LysMCre/+ CXCR4flox/-), or DKO (LysMCre/+ CXCR2-/CXCR4flox/-) mice (Ly5.2+) were mixed at a 1:1 ratio, and a total of 2 million cells injected
retroorbitally into lethally irradiated (1,000 cGy) wild type (Ly5.1+) recipient mice.
Antibiotics (trimethoprim-sulfamethoxazole, Alpharma, East Bridgewater, NJ) were
given for 2 weeks post-transplant.

3.3.3 Blood, bone marrow, or spleen analysis. Blood, bone marrow, and spleen cells
were quantified using a Hemavet automated cell counter (CDC Technologies, Oxford,
CT). Absolute neutrophil numbers were calculated assuming a blood volume of 1.8 ml
and a whole femur equivalent to 6% of the total bone marrow (40). Bone marrow
extracellular fluid was obtained by sequentially flushing both femurs with 400 μL icecold PBS and harvesting the supernatant after pelleting cells by centrifugation at 400 x g
for 2 minutes.
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3.3.4

Flow cytometry. Cells were stained by standard protocols with the following

antibodies (eBiosciences, San Diego, CA unless otherwise noted): Chimerism was
assessed using PerCP-Cy5.5-Ly5.1 (CD45.1) and allophycocyanin (APC)-Ly5.2 and one
or more of the following lineage markers: FITC-Ly6G (Gr-1, myeloid), PE-CD3e (T
lymphocytes), and APC-efluor780-CD45R (B220, B lymphocytes). A lineage cocktail of
FITC-conjugated Gr-1, B220, CD3e, and Ter119 (erythroid) was used to sort progenitor
cells. CXCR4 expression was assessed by incubating with anti-CD16/32 (Fc-block, BD
Biosciences, San Diego, CA) and biotin-conjugated CXCR4 (BD) followed by PEstreptavidin. Isotype-matched antibodies were used as negative controls. Data was
collected on a FACScan 5-color, 2-laser flow cytometer (BD Biosciences and Cytek
Development, Fremont, CA) using Cellquest software (BD) and analyzed with the
FlowJo software package (Tree Star, Ashland, OR).

3.3.5

Bone marrow leukocyte morphology. Gr-1+ Ly5.1+ (wild-type) or Ly5.2+

(CXCR2-/-) bone marrow cells were isolated using a Reflection high speed cell sorter (iCyt, Champaign, IL). Manual leukocyte differentials were performed in a blinded
fashion on Wright-stained cytospins prepared by cytocentrifugation of 200,000 sorted
cells at 400 rpm for 4 minutes. Photomicrographs were acquired using an E plan
100x/1.25 NA oil immersion objective, Microphot SA microscope, Digital Sight DS-Fi1
camera, and NIS-Elements F2.30 software, all from Nikon (Melville, NY) and
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conversion from color to black and white was done using Photoshop CS3 (Adobe
Systems, San Jose, CA) .

3.3.6

Colony-forming cell assay. Lineagelow Ly5.1+ (wild-type) or Ly5.2+ (CXCR2-/-)

bone marrow cells were isolated using a Reflection high speed cell sorter, and 350 (CFUC) or 3,000 (CFU-G) sorted cells were plated in 2.75 mL methylcellulose media
supplemented with a cocktail of recombinant cytokines or 10 ng/mL recombinant human
G-CSF (MethoCult 3434 or 3231, respectively; Stemcell Technologies, Vancouver, BC).
Duplicate cultures were incubated at 37°C for 14 days, after which colonies containing at
least 100 cells were counted in a blinded fashion.

3.3.7 Neutrophil mobilization. Recombinant human G-CSF was administered by twice
daily subcutaneous injection at a dose of 125 μg/kg/day for 5 days. Mice were analyzed
3-4 hours after the final injection on day 5. AMD3100 (Sigma, Saint Louis, MO) or
recombinant human GROβ, was administered as a single subcutaneous injection at doses
of 5 mg/kg and 100 μg/kg, respectively. Peripheral blood was obtained within 90
minutes prior to and 1-2 hours after the first injection.

3.3.8

Stromal cell chemokine expression profiling. Groups of 10 Col2.3-GFP or wild-

type mice were either left untreated or given G-CSF or vehicle for 7 days as indicated.
To isolate stromal cells, femurs were serially digested with collagenase (Worthington
Biochemical, Lakewood, NJ) as previously reported (41, 42). Stromal cells were then
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incubated with APC-CD45, APC-Ter119, and PE-CD31 (PECAM-1). 7-AminoActinomycin D (7AAD) was used to exclude non-viable cells. An average of 20,000
cells was sorted directly into TRIZOL LS reagent (Invitrogen, Carlsbad, CA), and RNA
was isolated according to the manufacturer’s instructions. RNA was amplified,
processed, and hybridized to Affymetrix (Santa Clara, CA) MOE430v2.0 GeneChip
microarrays per protocols of the Siteman Cancer Center Multiplexed Gene Analysis Core
Facility (Saint Louis, MO, http://pathology.wustl.edu/research/multiplexed.php). After
passing quality control, array data was normalized, annotated, and deposited at the
Siteman Cancer Center Bioinformatics Core Facility (http://bioinformatics.wustl.edu)
according to standard protocols. Expression data for all known chemokines, obtained
from at least 4 independent cell sorting experiments, was analyzed and compared using 2way ANOVA.

3.3.9

CXCL2 ELISA. Quantification of CXCL2 protein in bone marrow extracellular

fluid was performed using a commercially available enzyme-linked immunosorbent assay
(ELISA) kit from Peprotech (Rocky Hill, NJ) according to the manufacturer’s
instructions.

3.3.10 Statistical analysis. Significance was determined using Prism software
(Graphpad, La Jolla, CA) to perform two-tailed Student t tests assuming equal variance
or, where indicated, 1- or 2-way ANOVAs with Bonferroni post-testing. All data are
presented as the mean ± SEM.
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3.4

Results

3.3.1

Absence of CXCR2 results in abnormal retention of neutrophils in the bone

marrow.
Consistent with previous reports (34, 37), we observed marked neutrophilia in CXCR2-/mice maintained under SPF conditions (absolute neutrophil count: 4.63 ± 1.58 x 109/L
compared with 0.69 ± 0.06 x 109/L for congenic wild-type mice, P = 0.04). To determine
whether this phenotype was due to a cell intrinsic effect of a loss of CXCR2 signaling,
mixed bone marrow chimeras were generating by transplanting a 1:1 ratio of wild-type
and CXCR2-/- bone marrow cells into irradiated congenic mice (Figure 3-1A). Blood
neutrophil counts in the CXCR2-/- mixed chimeras were reduced in comparison to mice
reconstituted with wild-type cells alone (1.08 ± 0.08 x 109/L and 1.81 ± 0.29 x 109/L,
respectively; P = 0.003), suggesting that the neutrophilia in CXCR2-/- mice is the result of
a cell-extrinsic mechanism.
In the mixed chimeras, the number of CXCR2-/- neutrophils in the blood was
reduced compared to that in the bone marrow (Figure 3-1B, C). Whereas 65.3 ± 7.6% of
neutrophils in the bone marrow were derived from CXCR2-/- cells, only 25.0 ± 3.5% of
neutrophils in the blood were from CXCR2-/- cells (P < 0.0001). Of note, the number of
neutrophils in the spleen, another reservoir for neutrophils, was comparable between
CXCR2-/- and wild type cells (Figure 3-1C). Neutrophil trafficking from the bone
marrow was estimated by calculating the percentage of neutrophils in the blood relative
to the total number of neutrophils in the blood, bone marrow, and spleen (neutrophil
distribution index or NDI) (5). Consistent with previous studies (22, 43), under basal
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conditions 1.84 ± 0.32 % of wild-type neutrophils were present in the blood (Figure 31D). In contrast, the percentage of CXCR2-/- neutrophils in the blood was only 0.57 ±
0.18% (P = 0.02). No perturbation in other hematopoietic lineages was observed (Figure
1E). The number and cytokine responsiveness of myeloid progenitors in the bone
marrow were comparable between wild-type and CXCR2-/- cells (Figure 3-1F).
Myelokathexis is characterized by the accumulation of mature, often
hypersegmented or dysplastic, neutrophils in the bone marrow (10). Consistent with this
phenotype, we observed that the percentage of Gr-1hi SSChi cells, representing the most
mature neutrophils (44), relative to the total Gr-1+ myeloid cell population was higher for
CXCR2-/- cells compared with wild-type cells (Figure 3-2A, B). To confirm this finding,
CXCR2-/- and wild-type Gr-1+ myeloid cells were sorted from the bone marrow of the
mixed chimeras, and manual leukocyte differentials were performed. CXCR2-/- cells
showed an increase in the proportion of highly segmented, occasionally dysplastic
appearing, neutrophils (Figure 3-2C, D). Collectively, these data show that CXCR2
deficiency results in a myelokathexis-like phenotype with a cell-intrinsic retention of
neutrophils in the bone marrow.

3.4.2

Neutrophil mobilization by G-CSF is impaired in the absence of CXCR2.

Since it is the principal cytokine regulating emergency granulopoiesis (45), we next
measured the short-term (1-2 hour) and long-term (5 day) neutrophil responses to G-CSF
in the CXCR2-/- mixed chimeras. Consistent with previous reports (5, 22), administration
of G-CSF resulted in a 2.3 ± 0.5-fold increase in the blood of wild-type neutrophils
109

within two hours (Figure 3-3A). In contrast, there was no significant increase in CXCR2/-

neutrophils. After the full 5-day course of G-CSF, a significant increase in both wild-

type and CXCR2-/- neutrophils in the blood and spleen was observed in the mixed
chimeras (Figure 3-3B, C). Neutrophil release, as measured by the NDI, increased in
response to 5 day G-CSF treatment in both genotypes (compare Figure 3-1D with Figure
3-3D). However, the percentage of CXCR2-/- neutrophils in the blood after G-CSF
administration was still significantly lower than that for wild-type cells. These data show
that maximal blood neutrophil responses to G-CSF require CXCR2 signaling.

3.4.3

CXCR2 antagonistically regulates CXCR4-mediated neutrophil retention in

the bone marrow.
Previous studies have established a dominant role for CXCR4 signals in the retention of
neutrophils in the bone marrow (20, 22, 46-50). Since CXCR2 signaling has been shown
to regulate CXCR4 cell surface expression through heterologous desensitization and
receptor internalization (48, 51), we first assessed CXCR4 expression on CXCR2-/neutrophils. However, cell-surface expression of CXCR4 on bone marrow neutrophils
was similar between wild-type and CXCR2-/- cells (MFI: 107 ± 7 vs. 100 ± 12,
respectively; P = 0.4; Figure 3-4A), arguing against a simple mechanism in which the
absence of CXCR2 signals results in neutrophil retention through increased CXCR4
expression.
To more directly assess the relationship between CXCR2 and CXCR4 signals in
the regulation of neutrophil trafficking, we treated mixed chimeras with AMD3100, a
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small molecule CXCR4 antagonist. One hour after administration of AMD3100, a 3.8 ±
1.2-fold increase in wild-type neutrophils in the blood increased was observed (Figure 34B). In contrast, no increase in CXCR2-/- neutrophils in the blood was observed, despite
the fact that the majority of neutrophils in the bone marrow 1 hour after AMD3100
administration were of CXCR2-/- origin (Figure 3-4B, C). Accordingly, the NDI for
CXCR2-/- cells following AMD3100 administration (0.53 ± 0.21%) was dramatically
lower than that of wild-type cells (13.0 ± 3.27%; P = 0.02; Figure 3-4D), suggesting that
neutrophil mobilization in response to transient CXCR4 inhibition is dependent on
CXCR2.
We previously reported that mice carrying a myeloid-specific deletion of CXCR4
(MKO; LysMCre/+ CXCR4flox/-) displayed marked basal neutrophilia (22). To study the
genetic interaction of the CXCR2- and CXCR4-null alleles, we crossed CXCR4-MKO
mice with the CXCR2-/- mice to generate double knockout mice (DKO; LysMCre/+ CXCR2/-

CXCR4flox/-). Similar to the CXCR2-/- or CXCR4-MKO mice, DKO mice displayed

marked neutrophilia at baseline (data not shown). To examine the cell-intrinsic
properties of neutrophils lacking both CXCR2 and CXCR4, mixed chimeras were
generated as before using either DKO or, as a control, CXCR4-MKO bone marrow cells.
Recipient mice showed the expected level of donor engraftment in the bone marrow, with
52.1 ± 4.8% (DKO) or 62.2 ± 2.3% (CXCR4-MKO) of B lymphocytes derived from
mutant cells. As expected, mixed chimeras containing CXCR4-MKO cells showed a
marked redistribution of CXCR4-/- neutrophils into the blood (Figure 3-4E, F).
Surprisingly, a similar phenotype was observed in DKO chimeras, showing that loss of
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CXCR2 signals cannot rescue the neutrophilic phenotype of CXCR4-deficient
neutrophils.
To examine whether CXCR4 signals are required for mobilization by CXCR2
ligands, CXCR4-MKO mixed chimeras were given a single injection of the CXCR2
agonist GROβ (CXCL2). Whereas the number of wild-type neutrophils in the blood of
CXCR4-MKO chimeras increased 4.0 ± 0.4-fold 1 hour after GROβ administration, only
a minimal increase in CXCR4-/- neutrophils was observed, suggesting that neutrophil
release induced by CXCR2 activation is dependent on CXCR4 (Figure 3-4G).
Collectively, these data show that CXCR4 and CXCR2 antagonistically regulate
neutrophil release from the bone marrow, with CXCR4 playing a dominant role.

3.4.4 Expression of chemokines by osteoblasts and endothelial cells in the bone
marrow.
Previous studies have established that bone marrow stromal cells, in particular osteoblasts
and endothelial cells, are the major source of CXCL12 in the bone marrow (21, 25, 27,
42, 50, 52-54). However, the expression of other chemokines, specifically ELR+ CXCR2
ligands, in bone marrow stromal cells is unknown. To address this issue, we analyzed
stromal cells from the bone marrow of transgenic mice expressing GFP in osteoblast
lineage cells (Col2.3:GFP) (39, 42). Specifically, CD45low Ter119low stromal cells were
sorted into osteoblast (GFP+) and endothelial (CD31+) fractions, which were then
subjected to RNA expression profiling (Figure 3-5A). Of note, expression of endothelialor osteoblast-specific genes was appropriately enriched in the relevant cell fraction,
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demonstrating the fidelity of our sorting strategy (Tables 3-1 and 3-2). As reported
previously (27, 42), constitutively high expression of CXCL12 was observed in
osteoblasts and endothelial cells, with higher expression in osteoblasts (Figure 3-5B).
The CXCR2 ligands, CXCL1 (KC) and CXCL2 (MIP-2) also were constitutively
expressed in osteoblasts and endothelial cells, but with higher endothelial expression.
To examine the effect of G-CSF on chemokine expression in the bone marrow
microenvironment, endothelial cells were isolated from the bone marrow after G-CSF
administration. Osteoblasts were not sorted, since their number is markedly reduced by
G-CSF (27, 41, 42, 53). Of note, there was no change in bone marrow endothelial cell
number (P.K.G., Christopher, M.J., A.M.G., van Os, R., D.C.L., manuscript in
preparation). RNA expression profiling showed that CXCL2 expression in bone marrow
endothelial cells was induced 2.7 ± 0.3- fold by G-CSF, while CXCL12 mRNA was
modestly reduced to 47 ± 3% of its basal level; other chemokines remained unchanged
(Figure 3-5C). Consistent with the mRNA data, CXCL2 protein was detected in the bone
marrow supernatant at baseline with a trend to increased expression after G-CSF
administration (Figure 3-5D). Since osteoblast number is markedly reduced following GCSF administration, these data suggest that the balance of expression in the bone marrow
from pro-retention (CXCL12) to mobilizing chemokines (CXCL1 and CXCL2) may
contribute to neutrophil mobilization by G-CSF.
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3.5

Discussion

In the present study, we generated CXCR2-/- mixed bone marrow chimeras to characterize
the cell-intrinsic effect of CXCR2 deletion on neutrophil trafficking from the bone
marrow. We show that mature, occasionally hypersegmented, CXCR2-/- neutrophils, are
selectively retained in the bone marrow, reproducing a myelokathexis phenotype. In
contrast, CXCR2-/- mice display neutrophilia, suggesting augmented neutrophil
production and/or release. Studies of leukocyte adhesion deficiency (LAD) mice provide
a potential explanation for these discrepant results. Similar to CXCR2-/- mice, β2integrin-deficient mice (ITGB2-/-), which reproduce LAD type I in humans, exhibit
impaired emigration of neutrophils from the circulation to peripheral tissues and
neutrophilia when housed under SPF conditions (34, 55). In a series of elegant
experiments, Forlow et al (56) and Stark et al (57) showed that, in ITGB2-/- mixed
chimeras, as little as 10% wild-type neutrophils was sufficient to restore normal
neutrophil homeostasis. Moreover, they showed that neutrophil emigration into
peripheral tissues initiated a negative feedback loop that suppresses IL-17 and G-CSF
production. Thus, the emigration defect shared by CXCR2-/- and ITGB2-/- neutrophils may
disrupt this negative feedback loop and lead to the production of stress cytokines that
stimulate granulopoiesis. Consistent with this possibility, serum levels of IL-6 are
elevated in both CXCR2-/- and ITGB2-/- mice (34, 55).
Our results indicate that CXCR2 and CXCR4 coordinately regulate neutrophil
trafficking from the bone marrow. Previous studies have demonstrated that treatment of
neutrophils with CXCR2 ligands results in impaired CXCR4 signaling through
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heterologous desensitization and/or internalization (48, 51), suggesting that CXCR2
regulates neutrophil mobilization through modulation of CXCR4 signaling and/or
expression. Consistent with this possibility, Martin et al (47) and others (48, 49)
previously showed that neutrophil mobilization by the CXCR2 chemokine CXCL1 (KC)
was markedly increased by transient CXCR4 inhibition. Conversely, CXCR2-/neutrophils displayed almost no mobilization in response to transient CXCR4 inhibition
(Figure 3-4B-D). This surprising result suggests at least two possibilities: 1) loss of
CXCR2 may augment basal CXCR4 signaling, thereby rendering cells resistant to
AMD3100; 2) CXCR2 signals may function independently of CXCR4 to direct
neutrophil release following AMD3100-induced CXCR4 blockade. In support of the first
possibility, doubly deficient CXCR2-/- CXCR4-/- neutrophils display constitutive
mobilization (Figure 3-4E, F), demonstrating that CXCR2 signals are not required for
neutrophil mobilization in the complete absence of CXCR4 signals and suggesting a
dominant role for CXCR4 in the regulation of neutrophil trafficking from the bone
marrow. Consistent with this conclusion, the present study (Figure 3-4G) and our
previous report (22) show that neutrophil mobilization by the CXCR2 chemokine
CXCL2 (GROβ) is impaired in the complete absence of CXCR4 signals (i.e., in CXCR4-/neutrophils). Collectively, these data suggest that CXCR4 and CXCR2 signaling
antagonistically regulate neutrophil release from the bone marrow.
Previous studies have established that CXC12 is constitutively expressed by bone
marrow stromal cells, including osteoblasts and endothelial cells (21, 25, 27, 42, 50, 5254). Quantitative analysis of sorted stromal cell populations suggested that osteoblasts
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are the major source of CXCL12 in the bone marrow (27). Consistent with these
findings, our RNA expression profiling of sorted bone marrow endothelial cells or
osteoblasts demonstrated significantly higher expression of CXCL12 mRNA in
osteoblasts. The expression profiling data also showed that ELR+ CXC chemokines
CXCL1, CXCL2, and CXCL7 are constitutively expressed in bone marrow endothelial
cells and/or osteoblasts. However, in contrast to CXCL12, these chemokines are
expressed at higher levels in endothelial cells. Together, these data suggest a “tug-ofwar” model wherein endothelial-derived chemokines (primarily CXCR2 ligands) direct
neutrophil chemotaxis toward the vasculature for entry into the circulation, while
endosteal osteoblasts produce chemokines (primarily CXCL12) that promote neutrophil
retention (Figure 6). Under basal conditions, the balance of chemokine production favors
neutrophil retention in the bone marrow. Under stress conditions, expression of
inflammatory cytokines, most notably G-CSF, is increased (58). We and others
previously showed that G-CSF administration is associated with a marked suppression of
endosteal osteoblasts (27, 41, 42, 53). In addition, herein we show that CXCL2
expression is increased in bone marrow endothelial cells after G-CSF administration. The
net effect is a shift in the balance of chemokine production to the endothelium, thereby
promoting neutrophil release from the bone marrow.
In summary, this study provides evidence that ELR+ CXCR2 ligands are a second
chemokine family that, together with CXCL12, controls neutrophil trafficking from the
bone marrow. Although most cases of WS are associated with autosomal dominant,
gain-of-function mutations in CXCR4, several pedigrees have been reported that lack the
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characteristic mutations (9, 11, 14). Balabanian and colleagues reported a WS pedigree
with decreased expression of GPCR kinase-3 (GRK3), a protein that negatively regulates
CXCR4 signaling (59). Recently, homozygous, loss-of-function mutations in CXCR2
have been identified in a pedigree with isolated myelokathexis (George A. Diaz, personal
communication). Our data provide experimental evidence that loss-of-function mutations
in CXCR2 are sufficient to induce a myelokathexis phenotype in mice. Of potential
clinical relevance for the treatment of patients with myelokathexis and CXCR2 mutations,
our studies of CXCR2-/- neutrophils suggest that mobilization responses to AMD3100 or
G-CSF may be impaired.
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Figures and figure legends

Figure 3-1. Legend on next page.
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Figure 3-1. CXCR2-/- neutrophils are selectively retained in the bone marrow of
mixed chimeras. (A) Generation of mixed chimeras: bone marrow cells from wild-type
(WT) Ly5.1+ and CXCR2-/- Ly5.2+ mice (1 x 106 cells from each) were mixed in a 1:1 ratio
and transplanted into lethally irradiated congenic wild-type (Ly5.1+) recipients. Mice were
analyzed 6-8 weeks after transplantation. (B) Representative dot plots showing the
contribution of wild-type (Ly5.1+) and CXCR2-/- (Ly5.1-) cells to neutrophils (Gr-lhi) in the
blood and bone marrow. (C) Quantitation of mature neutrophils (Gr-1hiSSChi) in the
blood, bone marrow, and spleen. (D) The neutrophil distribution index (NDI) was
calculated to estimate the percentage of total body neutrophils in the blood using the
following formula: NDI = blood neutrophils/(blood + bone marrow + spleen neutrophils).
(E) Shown is the number of B lymphocytes (B220+) or T lymphocytes (CD3+) in the blood
(left panel) and B lymphocytes in the bone marrow (right panel). T lymphocyte
chimerism was assessed 6 months after transplantation (n = 3). (F) Shown is the
number of wild-type or CXCR2-/- CFU-C or CFU-G in the bone marrow (n = 3). Unless
otherwise noted, data represent the mean ± SEM of n = 27 (blood) or n = 6 (bone
marrow and spleen) mice from at least 3 independent transplantations.
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Figure 3-2. CXCR2 deficiency produces a myelokathexis-like phenotype.
(A) Representative dot plots of mixed chimera bone marrow showing the percentage of
Gr-1hi SSChi cells within the total Gr-1+ myeloid cell population for wild-type (WT, left
panel) or CXCR2-/- cells (right panel). (B) Shown is the percentage of Gr-1hi SSChi cells
within the total Gr-1+ myeloid cell population for n = 7 chimeric mice from 2 independent
transplants. (C) Representative photomicrographs of sorted wild-type (left panel) or
CXCR2-/- Gr-1+ cells (right panel). Scale bar = 20 µm. (D) Manual leukocyte differentials
of sorted cells from n = 5 mice from 2 transplants. The data represent the mean ± SEM.
***P < 0.001, 2-way ANOVA.
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Figure 3-3. Mobilization of CXCR2-/- neutrophils by G-CSF is impaired. (A) Mixed
chimeras (n = 5) were given a single injection of G-CSF (125 µg/kg) and the absolute
neutrophil count for each genotype was determined 1.5 hours after injection. (B) G-CSF
(125 µg/kg per day, twice daily) was administered to a separate cohort of n = 5 chimeric
mice for 5 days, and blood neutrophils were quantified. (C) The number of wild-type or
CXCR2-/- Gr-1+SSChi cells in the bone marrow (left panel) or spleen (right panel) after 5
days of G-CSF administration. (D) The calculated neutrophil distribution index after 5
days of G-CSF. The data represent the mean ± SEM. †P < 0.05, ‡P < 0.01 compared
with time 0; **P < 0.01, ***P < 0.001 compared with CXCR2-/- cells at the same time
point, 2-way ANOVA.
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Figure 3-4. CXCR2 and CXCR4 signals interact antagonistically to regulate
neutrophil release. (A) Representative dot plot (left panel) or the MFI of n = 5 mixed
chimeras (right panel) showing cell-surface CXCR4 expression of wild-type (Ly5.1+) and
CXCR2-/- (Ly5.1-) bone marrow cells gated on the Gr-1+SSChi population. (B) CXCR2-/mixed chimeras (n = 5) were given a single subcutaneous injection of AMD3100 (5
mg/kg) and neutrophils quantified at the indicated time. (C,D) Number of neutrophils in
the bone marrow and spleen and neutrophil distribution index at 1 hour after AMD3100
administration (n = 3). (E,F) LysMCre/+ CXCR4flox/- (MKO, n = 10) and LysMCre/+
CXCR4flox/- CXCR2-/- double knockout (DKO, n = 4) mixed chimeras were established as
described in Figure 1. Blood, bone marrow and spleen neutrophils and the neutrophil
distribution index were quantified 7 weeks after transplantation. (G) CXCR4-MKO mixed
chimeras (n = 3) were given a subcutaneous injection of GROβ (100µg/kg), and the
number of wild-type and CXCR4-/- neutrophils in the blood measured after one hour.
Data represent the mean ± SEM. ***P < 0.001, 1-way ANOVA (panels e and f). ‡P <
0.01 compared with time 0; **P < 0.01, ***P < 0.001 compared with wild-type cells at the
same time point, 2-way ANOVA (panels b and g).
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Figure 3-5. Legend on next page.
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Figure 3-5. CXCR2 ligands are produced by bone marrow stromal cells and
regulated by G-CSF. (A) Bone marrow endothelial cells (7AAD- CD45low Ter119low
CD31+) or osteoblasts (7AAD- CD45low Ter119low GFP+) were isolated by cell sorting from
Col2.3:GFP transgenic mice. Shown are representative dot plots depicting the sorting
strategy. (B) Shown is the normalized gene chip signal at baseline for all chemokines
with an average signal intensity of greater than 400 in at least one of the cell types.
Where more than one probe set existed, the highest signal was selected. Pf4 encodes
for CXCL4, Ppbp encodes for CXCL7, and Mif is a non-chemokine ligand for CXCR2
and CXCR4 (60). (C) Expression of CXCR2 and CXCR4 ligands in endothelial cells
from wild-type mice at baseline or after G-CSF administration. (D) CXCL2 protein in
bone marrow supernatant at baseline or after G-CSF was measured by ELISA (n = 4
mice per group). The dashed line represents the limit of detection for the assay. Data
represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 2-way ANOVA.
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Figure 3-6. Tug-of-war model of neutrophil trafficking from the bone marrow. See
text for details.
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Chapter 4

Summary and future directions
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4.1

Summary

A broad array of diseases are associated with dysregulation of the inflammatory response,
and neutrophils are a key initiating component of this response. Therefore, it is vital that
organisms maintain precise control of circulating neutrophil numbers to ensure adequate
protection against pathogens while minimizing damage to host tissue. Blood neutrophil
homeostasis is determined by the integrated control of neutrophil precursor proliferation
and differentiation in the bone marrow, release of mature neutrophils from the bone
marrow, and clearance of aged, senescent neutrophils from the circulation by
margination, transmigration across the endothelium, apoptosis, and phagocytosis.
Equally important is the ability to rapidly alter homeostatic levels of these processes in
order to mount an effective neutrophil response to infection or other stresses.
This thesis has increased our understanding of the role of the neutrophil
chemokine receptors CXCR2 and CXCR4 in the regulation of neutrophil homeostasis.
To study chemokine signaling in neutrophils, we used cells genetically deficient for
CXCR2, CXCR4, or both receptors. Our goals were: 1) to characterize the role of
CXCR2 and CXCR4 signaling in basal and stress granulopoiesis. 2) to characterize the
role of CXCR2 and CXCR4 signaling in neutrophil clearance. 3) to define the nature of
the interaction (if any) between CXCR2 and CXCR4 in the regulation of neutrophil
homeostasis. 4) to identify the chemokines produced in the bone marrow, their cellular
source, and how they are regulated.
Our results show that CXCR4 is a dominant, common pathway regulating
neutrophil release from the bone marrow under basal and stress conditions, but it is not
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essential for neutrophil clearance from the circulation (Chapter 2). CXCR2 opposes
CXCR4 in the regulation of neutrophil release from the bone marrow. It is required for
egress into the tissues and proper sensing of neutrophils by tissue phagocytes, but cellintrinsic CXCR2 signals play a minor role, if any, in the regulation of neutrophil
production (Chapter 3). CXCR2 and CXCR4 ligands are highly produced by bone
marrow endothelial cells and osteoblasts. Their expression pattern and regulation by GCSF suggests a tug-of-war model where the balance of pro-retention chemokines
produced by osteoblasts and mobilizing chemokines produced by the endothelium
regulates the level of neutrophil release from the bone marrow (Chapter 3). Our data in
genetic knockout mice supports a causative role for CXCR2 and CXCR4 mutations in the
pathogenesis of the human disease WHIM syndrome.

4.1.1

CXCR4 myeloid conditional knockout mice

A significant amount of genetic and pharmacologic data in humans and mice suggested
that CXCR4 may be a key retention signal for neutrophils in the bone marrow. Even
more intriguing, a series of studies by Dr. Sara Rankin and colleagues had suggested that
modulation of CXCR2 and CXCR4 signaling may regulate the return of senescent
neutrophils to the bone marrow where they are ultimately cleared by apoptosis and
phagocytosis (1, 2). However, the interpretation and analysis of all the existing data was
complicated by limited samples from patients with WHIM syndrome, perinatal lethality
in CXCR4-deficient mice, the potential confounding effects of CXCR4 signaling in
precursor cells or other lineages in the bone marrow, ex vivo manipulation and aging of
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neutrophils, and the inherent limitations, such as off-target effects or incomplete
inhibition, of drugs or antibodies. In Chapter 2, we utilized mice with a conditional
deletion of CXCR4 restricted to cells of the myeloid lineage to assess the function of
CXCR4 in neutrophils and overcome many of these limitations.
Using these mice, we confirmed that CXCR4 acts as a key retention signal that
negatively regulates neutrophil trafficking from the bone marrow. We also show that
although CXCR4 mediates homing of circulating neutrophils to the bone marrow, this
site is not essential for neutrophil clearance, suggesting that other organs (spleen, liver,
lung) can compensate for impaired bone marrow clearance without a requirement for
CXCR4.
The role of CXCR4 in neutrophil mobilization in response to infection or stress is
not clear. In general, there is evidence both for and against the presence of distinct
pathways in basal versus stress granulopoiesis, between various sites of infection, and
between different bacterial and fungal pathogens. To answer the question of whether
CXCR4 is a final common pathway that mediates both basal and stress granulopoiesis,
the neutrophil response of the myeloid conditional CXCR4 knockout mice to several
important classes of inflammatory mediators (cytokines, G-CSF; chemokines, CXCL2)
and a murine model of lethal bacterial infection (Listeria monocytogenes) was measured.
The results suggested that disruption of CXCR4 signaling is the mechanism of neutrophil
mobilization in response to these diverse classes of stimuli. Of note, consistent with the
normal homeostatic clearance of CXCR4-deficient neutrophils, CXCR4 was not required
for neutrophil emigration into the peritoneum in response to L monocytogenes infection.
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4.1.2

CXCR2 chemokines mediate neutrophil release

Having shown that CXCR4 seems to be a master retention signal for neutrophils in the
bone marrow, we hypothesized that other signals must exist that oppose CXCR4 and
direct the key steps of neutrophil mobilization: disruption of adhesive interactions with
the bone marrow extracellular matrix, chemotaxis toward the vasculature, and
transmigration across the endothelial barrier into the circulation. The alternative
hypothesis is that constitutive mobilization is the default program that occurs by mass
action of neutrophil production in the bone marrow and random chemokinesis. Under
this model, CXCR4 evolved to limit excessive inflammation and tissue damage from
circulating neutrophils. Work presented in Chapter 3 suggests that CXCR2 may be one
such opposing signal.
Given the essential role of CXCL12, it seemed logical that other chemokines
might play a role in regulating neutrophil mobilization. CXCR2 chemokines were
attractive candidates because of the high expression of CXCR2 on mature neutrophils and
the diverse neutrophil functions mediated by CXCR2 signals. Furthermore, CXCR2
ligands were already known to be rapid and potent mobilizing agents. However, the
mechanism of their action (activation versus chemotaxis, cell-extrinsic versus cellintrinsic) and whether they had a more general, endogenous role in basal neutrophil
release or neutrophil mobilization by other classes of agents was unclear. At about the
same time, mutations in CXCR2 associated with myelokathexis were reported. Together,
this data supported the idea that CXCR2 positively regulated neutrophil release from the
bone marrow.
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Stromal cells in the bone marrow are likely to produce a number of molecules, in
addition to CXCL12, that are important in regulating neutrophil trafficking. In particular,
endothelial cells are highly transcriptionally active and are known to perform a variety of
intercellular signaling functions, including mediation of neutrophil extravasation, in the
peripheral circulation. Their function as a physical barrier to the circulatiion predicts that
endothelial cells play a key role in regulating neutrophil release. To address these
possibilities, we performed a survey of gene expression in osteoblasts and endothelial
cells and measured endothelial cell changes in response to G-CSF using gene expression
arrays as described in Chapter 3. Although additional candidate molecules need to be
assessed, an unbiased analysis of gene expression changes using SAM and a curated
assessment of all chemokines provided further evidence that the CXCR2 was a key
positive regulator of neutrophil release. The CXCR2 chemokines CXCL1, CXCL2, and
CXCL7 were highly expressed, with higher expression in endothelial cells and increased
CXCL2 expression in endothelial cells after G-CSF.
CXCR2-deficient neutrophils in mixed bone marrow chimeras were used to
confirm this potential role for CXCR2 in neutrophil release. As mentioned above, the
cause of the myeloid expansion in CXCR2-deficient mice is not clear (3-5). Although
further experiments need to be done to confirm these conclusions, our data suggest that
the neutrophilia in these mice is caused by an interruption of the neutrostat feedback loop
involving suppression of IL-23, IL-17, and G-CSF production by phagocytosis of
neutrophils in peripheral tissues. Our results argue against excessive cell-intrinsic
proliferation or passive accumulation of CXCR2-deficient neutrophils as an explanation
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for the neutrophilia. Alternatively, CXCR2 may interact with other, as yet
uncharacterized components of this feedback loop. Specifically, CXCR2 may be
important for interactions with endogenous bacteria or clearance of subclinical infections
that affect cytokine production and neutrophil homeostasis. The environmental
conditions of mice or humans with CXCR2 mutations (germ-free, specific pathogen-free,
or the normal range of pathogens in the everyday world), must be considered when
making generalizations from observed alterations in neutrophil counts. Finally, CXCR2
signaling in non-hematopoietic cells, particularly endothelial cells, may play a role in
regulating neutrophil and lymphocyte homeostasis.
Our results suggest that CXCR2 is a second chemokine pathway that positively
regulates neutrophil release. We show that CXCR2-deficient neutrophils reproduce a
myelokathexis phenotype consistent with the recently described human mutations.
CXCR2 appears to play a role in the stress granulopoiesis response to G-CSF. The data
indicate that CXCR2 is more important in regulating the immediate (minutes to hours)
release of neutrophils after G-CSF treatment. CXCR2 has a more minor role in
neutrophil mobilization after prolonged (days) of G-CSF, probably because of the
additional effects of G-CSF-induced proliferation, transcription, and microenvironmental
changes in the bone marrow.
CXCR2 and CXCR4 interact antagonistically to regulate neutrophil release from
the bone marrow. However, CXCR4 appears to play a dominant role, as neutrophils
lacking both CXCR2 and CXCR4 still display constitutive mobilization. The importance
of CXCR2 signaling in neutrophil trafficking likely decreases with increased magnitude
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or duration of CXCR4 inhibition. Our experiments did not definitively answer whether
CXCR2 antagonizes CXCR4 signaling through heterologous interactions. On one hand,
we did not observe any alteration in CXCR4 expression in the absence of CXCR2,
arguing against heterologous regulation of receptor expression. In contrast, CXCR2 had
no effect on neutrophil counts in the complete, genetic absence of CXCR4, consistent
with a mechanism for CXCR2 that acts through CXCR4. One such mechanism is
heterologous desensitization or internalization.
Chemokine receptors, like many GPCRs, can undergo heterologous regulation of
their signals at many different levels. They can homo- or hetero-dimerize or even form
higher oligomers. Desensitization or internalization signals generated by one receptor
can cross-desensitize or –internalize other related receptors. The regulatory mechanisms
in play are highly dependent on the cell type, specific receptor, and environmental
mileau. Therefore, additional experiments will be required to determine what, if any,
interactions there are between CXCR2 and CXCR4 that are important for the phenotype
observed in CXCR2-deficient neutrophils. Of note, heterologous desensitization between
CXCR4 and CXCR2 has been demonstrated in ex vivo cultured monocytes (6) and
neutrophils (7). Wild-type or WHIM-mutant CXCR4 can form dimers at the cell surface
in cell lines (8). Recently, our collaborator Dr. George Diaz has demonstrated physical
interaction between CXCR4 and CXCR2 (unpublished data) in neutrophils.
Our results show that the integration of CXCR2 and CXCR4 signals by
neutrophils in the bone marrow is a key pathway regulating their release. Our data and
others suggest that this signaling axis may be important in immunodeficiency, infectious
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and inflammatory disease. The CXCR2- and CXCR4-deficient mouse models described
in this thesis could be tested in additional models of infection to further investigate this
possibility. Drugs that activate or inhibit these receptors should be tested in models of
acute (sepsis, ARDS) or chronic (rheumatoid arthritis) inflammatory disease. Indeed, our
data suggest that prolonged G-CSF treatment but not AMD3100 treatment would be
effective in treating patients with myelokathexis and CXCR2 mutations. The efficacy of
chronic AMD3100 treatment in CXCR2-deficient neutrophils needs to be tested.
Conversely, either AMD3100 or G-CSF (the currently used therapy) would be effective
in other genotypes of WHIM syndrome.

4.2

Future directions

4.2.1

Expression of chemokines and other molecules by bone marrow stromal cells

The production of CXCL1 and CXCL2 in bone marrow endothelial cells and osteoblasts
needs to be confirmed. Several methods are currently being employed to accomplish this
goal. Bone marrow stromal cells will be sorted as described in Chapter 3 and expression
of CXCL1, CXCL2, CXCL7, and CXCL12 will be measured by qRT-PCR. We are also
currently working to develop a flow cytometry assay to measure CXCL1 and CXCL2 in
endothelial cells. Finally, as was done with CXCL12, Adam Greenbaum in our
laboratory is working to stain bone marrow histologic sections for CXCL1 or CXCL2
and co-localize these proteins with endothelial cell or osteoblast-specific markers. We
will also look at these histologic sections to assess any changes in the overall architecture
of the bone marrow after G-CSF administration or inhibition of CXCR4 by AMD3100.
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Is CXCR4 inhibition associated with increased amounts of neutrophils near the
vasculature or absence of neutrophils near the endosteum? When these assays are
developed, we will also measure chemokine expression after shorter courses of G-CSF to
try to explain the differences observed in CXCR2-deficient neutrophils after short- versus
long-term G-CSF. Alternatively, a GFP reporter construct could be knocked in to the
CXCL2 locus and GFP expression measured by flow cytometry or histology to confirm
the cell types that express CXCL2 and its regulation by G-CSF.
Although the chemokine expression data supports the tug-of-war model for
neutrophil release, the requirement for these chemokines has not been demonstrated. To
determine the biological significance of chemokine expression in specific stromal cell
subsets, Adam Greenbaum is developing a transgenic mouse system with a floxed
CXCL12 allele that will allow for osteoblast- (using OSTERIX-CRE mice) or endothelia(using TIE2-CRE mice) specific deletion of CXCL12. Our model predicts increased
neutrophil release with osteoblast deletion and normal or decreased release with
endothelial deletion. If this strategy proves successful, we would pursue a conditional
deletion model of CXCL2 and possibly even CXCL1. An alternative but less desirable
strategy would be to overexpress these chemokines using transgenes specific for
osteoblasts or endothelial cells. These types of models are subject to dysregulated
expression and leaky expression outside of the target cell population. Furthermore, some
of these approaches have already been reported in the literature (9). Actually, this report
supports the tug-of-war model since vascular CXCL12 expression in the absence of
osteoblast CXCL12 resulted in decreased myeloid cells in the bone marrow. However, it
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is clear from the CXCR4 myeloid conditional knockout mice and our CXCL12
expression data that under normal conditions CXCL12 derived from osteoblasts acts as a
retention signal that far outweighs any pro-mobilizing effect of CXCL12 produced by
bone marrow endothelial cells.
We will also perform further analysis on our existing gene chip data and
expression arrays performed in Dr. Tim Ley’s laboratory on neutrophils differentiated in
vitro (10) to search for additional molecules that may regulate basal or G-CSF induced
neutrophil release from the bone marrow.

4.2.2

Mouse models of WHIM syndrome

Retroviral overexpression of WHIM-mutant CXCR4 has been reported (11) but is subject
to confounding effects of dysregulated expression, insertional mutagenesis, and the
xenotransplant setting. A long standing but yet to be accomplished goal of this work has
been to develop a “knock in” transgenic mouse model of WHIM syndrome by expressing
the CXCR4 R334X mutant under the control of the endogenous CXCR4 promoter. Our
preliminary data indicate that this locus is extremely resistant to homologous
recombination, as only one out of more than 1,000 neomycin-resistant ES clones
displayed targeted recombination. Although human WHIM syndrome is not a highly
lethal disease, another possibility is that in the mouse ES cells this mutation is toxic.
CXCR4 is expressed throughout development, including in ES cells, and the mutation
acts in a dominant fashion. One report demonstrated that merely slightly altered levels of
CXCR4 signaling could affect developmental processes (12). In mouse embryos,
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expression of mutant CXCR4 impairs viability. In embryos generated from chimeric
blastocysts derived from the one correctly targeted ES clone, a high level of chimerism as
assessed by coat color resulted in lethality. Using an albino B6 recipient blastocyst, 3/25
mice with black eyes were dead at birth, while the surviving 22 mice were all white. In
chimeric pups with chimerism assessed by expression of a lacZ transgene in red blood
cells, 2/10 mice displayed some lacZ activity, but this level of chimerism resulted in
infertility and resultant inability to obtain germline transmission of the mutation.
Current efforts by Ryan Day in the lab are focused on generating inducible
heterozygous expression of the mutant CXCR4 so that prior to Cre induction mice will
merely be haploinsufficient for CXCR4. As described above, CXCR4+/- mice are
essentially normal. Such a system for other genes has been reported in the literature, and
we are using a construct similar to the one described (13). If these mice can be
generated, they would confirm that CXCR4 mutations are responsible for the
pathogenesis of WHIM syndrome. The mechanisms of viral infection, brain tumors, and
altered B lymphocyte function in addition to the altered neutrophil trafficking could be
dissected. The mice would provide a tool to profile the intracellular signaling molecules
that mediate neutrophil release. For example, it is unclear whether GRK6, GRK3 or both
are the key regulators of CXCR4 desensitization (14, 15).

4.2.3

Importance of stromal CXCR2 expression

In the process of generating chimeras with CXCR2-deficient neutrophils, we predicted
that wild-type mice reconstituted with CXCR2-/- hematopoiesis would recapitulate the
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neutrophilic phenotype of CXCR2-/- mice. However, some chimeras were generated with
only CXCR2-/- cells, and, to our surprise, these mice were neutropenic with no evidence
for myeloid expansion. This suggests two possibilities: 1) Given the data in germ-free
CXCR2-/- - mice, there may be a critical period during which subclinical infection or
endogenous bacteria can become dysregulated and induce excessive cytokine production.
This may occur during the neonatal period. Alternatively, the conditioning regimen for
bone marrow transplant may interrupt this process. 2) CXCR2 expression on nonhematopoietic, radio-resistant cells (such as endothelial cells) may prevent neutrophilia.
To address the role of non-hematopoietic CXCR2 signaling in neutrophil homeostasis,
we are generating chimeras derived from CXCR2-/- recipient mice reconstituted with
wild-type cells, or CXCR2-/- cells transplanted back into CXCR2-/- recipients as a
control. These experiments may demonstrate a novel role for endothelial CXCR2 in
neutrophil homeostasis.

4.2.4

Signaling studies

As discussed above, our experiments did not completely determine the role of
heterologous interactions between CXCR2 and CXCR4 in the regulation of neutrophil
trafficking. We will use CXCR2- or CXCR4- deficient neutrophils in chemotaxis and
calcium flux assays to measure any alterations in signaling in the absence of one of these
two receptors. If heterologous interactions are responsible for myelokathexis in CXCR2-/mice or humans, we would predict that CXCR4 signaling would be increased in the
absence of CXCR2. We will attempt to measure signaling in conditions that mimic either
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basal or stress conditions. According to a recent report, β-arrestin transmits CXCR4
signals through ERK phosphorylation (16), so we will also attempt to measure CXCR4
signaling in freshly isolated neutrophils using a phosphoflow assay previously utilized in
LKS cells by our lab (17).
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